UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,Washington, D.C. 20549

SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE
SECURITIES ACT OFProxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
(AMENDMENT No.__)
Amendment No. ___)
Filed by the Registrant [X]
Filed by a party other than the Registrant [   ]
Check the appropriate box:
[   ] Preliminary proxy statement
[X] Definitive proxy statement
[   ] Definitive additional materials
[   ] Soliciting materials pursuant to Sec. 240.14a-11(c)or Sec. 240.14a-12

Imaging Diagnostic Systems, Inc.
(Name of Registrant as Specified in its Charter)

Payment of Filing Fee (Check the Appropriate Box):
[X]           No fee required.
[   ]$125           $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), or 14a-6(j)(2).
[   ]$500           $500 per each party to the controversy pursuant to
Exchange Act Rule 14a-6(i)(3).
[   ]Fee computed on table below per Exchange Act Rules
14a-6(i)(4) and 0-11.

(1)Title of each class of securities to which
transaction applies:______________________
(2) Aggregate number of securities to which transaction applies:______________________
(2)Aggregate number of securities to which
transaction applies:______________________
(3)Per unit price or other underlying value of
transaction computed pursuant to Exchange
Act Rule 0-11 __/
(4)Proposed maximum aggregate value of
transaction:_______________________
(5)Total fee paid:____________________

[   ]           Fee paid previously with preliminary materials.
[   ]Check box if any part of the fee is offset as
provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.
Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)           Amount previously paid:___________________

(2)Form, Schedule or Registration Statement No.:_____________

(3)Filing Party:________________

(4)Date Filed: October 3, 2006



IDSI Logo



IMAGING DIAGNOSTIC SYSTEMS, INC.
5307 NW 35th Terrace
6531 NW 18th Court
Plantation,Fort Lauderdale, Florida 3331333309

October 3, 2006November 13, 2008

Dear Fellow Shareholder,

We cordially invite you to attend our Annual Meeting of Shareholders of Imaging Diagnostic Systems, Inc., (“IDSI”("IDSI") at 9:00 AM local time on November 8, 2006,December 29, 2008, at 6531Sheraton Suites Cypress Creek, 555 NW 1862ndth Court, Plantation, Street, Fort Lauderdale, Florida, and we are asking for your participation.  You do not need to attend the meeting to participate.  However, it is important that you take a few minutes to read the enclosed materialproxy materials and then vote your shares.

In February 2005Pursuant to new rules promulgated by the Securities and Exchange Commission, we have elected to provide access to our proxy materials over the Internet.  Accordingly, we will mail, on or about November 18, 2008, a Notice of Internet Availability of Proxy Materials to our stockholders of record and beneficial owners at the close of business on November 12, 2008.  On the date of mailing of the Notice of Internet Availability of Proxy Materials, all stockholders and beneficial owners will have the ability to access all of the proxy materials on a website referred to in the Notice of Internet Availability of Proxy Materials.  These proxy materials will be available free of charge.

As many of you know, I returned to IDSI in April 2008 and immediately secured a new Sixth Private Equity Credit Agreement with Charlton Avenue, LLC for up to $15 million and then in August 2008 secured a $800,000 convertible debenture facility to raise funds required for the clinical collection of the PMA data and the submission of the PMA application.  This debenture facility was amended in October 2008 to $400,000.  We have sold a $400,000 8% Senior Convertible Debenture to Whalehaven Capital Fund Limited (“Whalehaven”), and we filed an S-1 Registration Statement to register the underlying shares for the conversion of the $400,000 debenture, interest and related warrants.

We have faced many challenges over our 14-year history.  The development of an innovative medical imaging technology is a complicated, time consuming and very expensive process.  Since inception, substantially all of our necessary funding has come from the proceeds of the sale of common stock, convertible preferred stock and convertible debentures.  The convertible securities, with the exception of the Whalehaven Convertible Debentures, were all converted into common stock.  Since January 2001 we have primarily used a series of private equity credit agreements with Charlton Avenue, LLC, an institutional investor, to raise the capital necessary to fund the Company's operations.  The use of private equity credit agreements is dilutive as the investor sells our shares into the market.

Over the course of the last several years we asked for, and subsequently received, your approval to increase the number of authorized IDSI common stock shares. Atshares so that time we anticipated that revenues would have been a significant source of cash by now but commercialization has continuedbe able to be slower than expected.

The commercial efforts in China have not metutilize our expectations primarily because reimbursement forprivate equity credit agreements with Charlton to fund the CTLM® procedure was not granted in a timely fashion although we expect it any day. We also enhanced our China commercialization efforts by establishing a Representative Office in Beijing and staffing it for direct support of service, marketing and distributor management.

IDSI has, however, made good progress on other initiatives in the last 12 months as recounted in our September 2006 10-K filing. We have begun collecting PMA clinical cases at several sites in the U.S. Cases are being collected with the latest version of the CTLM® system. In addition to this U.S. effort we have logged over 7,000 breast studies globally.

To garner the maximum shareholder value we recently licensed LILA technology to a company in the small animal imaging markets. As we stated in 2004, IDSI’s main focus is on human breast scanning and women’s health opportunities. The LILA developments in small animal scanning can be best realized in the hands of a company with experience in those markets. As announced, IDSI will receive an up-front payment and could receive substantial royalties as products become commercialized.

We have depended on shareholders to support the Company since its inception.Company.  We had hoped that the shares previously authorized could have metwould be sufficient to meet our funding needs, but with the unforeseen delays in our PMA process, and without more cash from commercialization, which has continued to be slower than expected, and given that theour stock share price has held at much lower levelsdeclined more than we


anticipated, we will require additional authorized shares to fund IDSI in its normal course of business and to provide reasonable strategic reserves.

The dynamics of IDSI have changed since the retirement of our former CEO, Tim Hansen in January, the retirement of director Edward Rolquin, in February, and the resignations of the three independent directors, Jay Bendis, Patrick Gorman, and Sherman Lazrus, in accordance with a request initiated by our investment banker as a condition for additional funding.

Our number one priority is the submission of our PMA application to the FDA which we expect to occur in December 2008.  We have outsourced additional experts as needed to expedite this process.  We have begun a more aggressive international sales and marketing program to appoint new distributors, terminate non-performing distributors and to offer introductory incentives to achieve sales.  A temporary halt has been placed on new projects and all efforts are directed to the PMA filing and international sales.  Because of our cost cutting initiatives, we anticipate a 69% savings in office rent expense as a result of our decision to lease a smaller facility.

In this regard, we are asking our shareholders to approve a proposal to amend our Articles of Incorporation to increase the authorized common stock from 300,000,000450,000,000 to 450,000,000950,000,000 shares.  I have confidence inam confident that you will continue your continued support by voting in favor of this proposal.



THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS APPROVING THIS PROPOSAL.

Your vote is important and I urge youextremely important.  We appreciate your taking the time to vote promptly.  After reading the Proxy Statement, please vote, at your sharesearliest convenience by telephone or Internet, or request a proxy whether or notcard to complete, sign and return by mail.  If you plandecide to attend the meeting. After you read thisAnnual Meeting and would prefer to vote by ballot, your proxy statement, please indicate onwill be revoked automatically and only your vote at the proxy card the manner in which youAnnual Meeting will be counted.  YOUR SHARES CANNOT BE VOTED UNLESS YOU VOTE (I) BY TELEPHONE, (II) BY INTERNET, (III) REQUEST A PAPER PROXY CARD, TO COMPLETE, DATE, SIGN AND RETURN BY MAIL, OR (IV) ATTEND THE ANNUAL MEETING AND VOTE IN PERSON.

I want to have your shares voted. Then date, sign and mail the proxy card in the postage-paid envelopeassure you that is provided. If you sign and return your proxy card without indicating your choice, itI will be understood that you wish to have your shares voted in accordancedo my best with the recommendationshelp of IDSI's management to achieve our strategic goals.  Thank you for your continued support of IDSI and we hope you will attend the Board of Directors.meeting.


Sincerely,

/s/ T.Linda B. HansenGrable
TimothyLinda B. HansenGrable
Chief Executive Officer






IDSI Logo

IMAGING DIAGNOSTIC SYSTEMS, INC.
5307 NW 35th Terrace
6531 NW 18th Court
Plantation,Fort Lauderdale, Florida 3331333309

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
To Be Held on November 8, 2006December 29, 2008

TO THE SHAREHOLDERS OF IMAGING DIAGNOSTIC SYSTEMS, INC.

NOTICE IS HEREBY GIVEN that the Annual Meeting of Shareholders of Imaging Diagnostic Systems, Inc., a Florida corporation (the “Company”"Company"), will be held on Wednesday, November 8, 2006,Monday, December 29, 2008, at 9:00 A.M. local time at our corporate offices,the Sheraton Suites Cypress Creek, located at 6531555 NW 18th Court, Plantation,62nd Street, Fort Lauderdale, Florida, for the following purposes:

1.To elect sixtwo directors until the next annual meeting;

2.To approve a proposal to amend the Company’sCompany's Articles of Incorporation to increase the number of authorized shares of the Company’sCompany's common stock, no par value, from 300,000,000450,000,000 to 450,000,000;950,000,000;

3.To consider and act upon a proposal to adopt the Company's 2007 Non-Statutory Stock Option Plan;

4.To ratify the appointment by the Board of Directors of Sherb & Co., LLP as independent auditors of the Company for the fiscal year ending June 30, 2007;2009; and

4.5.To conduct any other business properly brought before the meeting.

 These items of business are more fully described in the Proxy Statement accompanying this Notice.

The Board of Directors has fixed the close of business on Thursday, September 7, 2006Wednesday, November 12, 2008 as the record date.  Only shareholders of record at the close of business on that date may vote at the meeting and any adjournment or postponement thereof.

 By Order of the Board of Directors
  
 
/s/ Allan L. Schwartz
 Allan L. Schwartz, Secretary

Plantation,Fort Lauderdale, Florida
October 3, 2006November 13, 2008

ALL SHAREHOLDERS ARE CORDIALLY INVITED TO ATTEND THE MEETING IN PERSON.PERSON AS YOUR VOTE IS EXTREMELY IMPORTANT.  HOWEVER, TO ASSURE YOUR REPRESENTATION AT THE MEETING, YOU ARE URGED TO MARK, SIGN, DATE AND RETURN THE ENCLOSED PROXYVOTE BY TELEPHONE OR INTERNET AS PROMPTLY AS POSSIBLE IN THE POSTAGE PREPAID ENVELOPE ENCLOSED FOR THAT PURPOSE. ANY SHAREHOLDER ATTENDING THE MEETINGPOSSIBLE. ALTERNATIVELY, YOU MAY VOTE IN PERSON EVEN IF HE OR SHE RETURNEDREQUEST A PROXY. PLEASE NOTE, HOWEVER, THAT IF A BROKER, BANK OR OTHER NOMINEE HOLDS YOUR SHARES OF RECORDPAPER PROXY CARD, WHICH YOU MAY COMPLETE, SIGN AND YOU WISH TO VOTE AT THE MEETING, YOU MUST OBTAIN FROM THE RECORD HOLDER A PROXY ISSUED IN YOUR NAME.RETURN BY MAIL.



IMAGING DIAGNOSTIC SYSTEMS, INC.
6531 NW 18th Court
Plantation, Florida 33313TABLE OF CONTENTS


Page No
Information Concerning Solicitation and Voting
3
Security Ownership of Certain Beneficial Owners and Management And Related Stockholder Matters
8
Proposal 1:  Election of Directors
10
Nominees for Election of Directors
12
Compensation of Directors – Fiscal 2008
13
Management – Directors and Executive Officers
18
Executive Compensation
19
Proposal 2:  Increase in the Number of Authorized Shares of Common Stock
24
Proposal 3:  Adoption of the Company's 2007 Non-Statutory Stock Option Plan
26
Proposal 4:  Ratification of Appointment of Independent Auditors
29
Deadline for Receipt of Shareholder Proposals
29
Other Matters
29
Appendix A
30




PROXY STATEMENT
FOR THE ANNUAL MEETING OF SHAREHOLDERS
To Be Held on November 8, 2006December 29, 2008

INFORMATIONINFORMATION CONCERNING SOLICITATION AND VOTING


WHY AM I RECEIVING THESE MATERIALS?

This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board”"Board") of Imaging Diagnostic Systems, Inc. (the “Company”"Company" or “IDSI”"IDSI") for the Annual Meeting of Shareholders to be held on Wednesday, November 8, 2006,Monday, December 29, 2008, at 9:00 A.M. local time at our corporate offices,the Sheraton Suites Cypress Creek, located at 6531555 NW 18th Court, Plantation,62nd Street, Fort Lauderdale, Florida, or any adjournment or adjournments thereof, for the purposes set forth herein and in the accompanying Notice of Annual Meeting.

In accordance with rules and regulations recently adopted by the SEC, instead of mailing a printed copy of our proxy materials to each stockholder of record, we are now furnishing proxy materials to our stockholders on the Internet. If you received a Notice of Internet Availability of Proxy Materials by mail, you will not receive a printed copy of the proxy materials other than as described below. Instead, the Notice of Internet Availability of Proxy Materials will instruct you as to how you may access and review all of the important information contained in the proxy materials. The Company intendsNotice of Internet Availability of Proxy Materials also instructs you as to how you may submit your proxy by telephone or over the Internet. If you received a Notice of Internet Availability of Proxy Materials by mail thisand would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting such materials included in the Notice of Internet Availability of Proxy Statement andMaterials.

It is anticipated that the accompanying proxy cardNotice of Internet Availability of Proxy Materials is first being sent to stockholders on or about October 7, 2006November 18, 2008.  The proxy statement and the form of proxy relating to all shareholders entitledthe 2008 Annual Meeting are first being made available to vote at the Annual Meeting.stockholders on or about November 19, 2008.

WHO CAN VOTE AT THE ANNUAL MEETING?

Only shareholders of record at the close of business on Thursday, September 7, 2005Wednesday, November 12, 2008 (the “Record Date”"Record Date"), are entitled to receive notice of and to vote at the annual meeting.  On the Record Date, there were issued and outstanding 247,676,633374,264,685 shares of Common Stock.

WHO CAN ATTEND THE ANNUAL MEETING?

All shareholders as of the record date, or their duly appointed proxies, may attend the annual meeting.  Seating will begin at 8:30 AM and the meeting will commence at 9:00 AM.  Each shareholder may be asked to present valid picture identification, such as a driver’sdriver's license or passport.  Cameras, recording devices and other electronic devices will not be permitted at the meeting.



Please note that if you hold your shares in “street name”"street name" (that is, through a broker or other nominee), you will need to bring a copy of your brokerage statement reflecting your stock ownership as of the record date and check in at the registration table at the meeting.

WHAT AM I VOTING ON?

There are threefour matters scheduled for a vote:

 ·Election of sixtwo directors
 ·Approval of a proposal to amend the Company’sCompany's Articles of Incorporation to increase the number of authorized shares of the Company’sCompany's common stock, no par value, from 300,000,000450,000,000 to 450,000,000.950,000,000.
·To adopt the Company's 2007 Non-Statutory Stock Option Plan
 ·Ratification of Sherb & Co., LLP as independent auditors of the Company for its fiscal year ending June 30, 2007.2009.

2


HOW DO I VOTE?

You may either vote “For”"For" or “Withhold”"Withhold" for each of the nominees to the Board of Directors.  You may vote “For”"For" or “Against”"Against" or “Abstain”"Abstain" for approval of an amendment to the Articles of Incorporation to increase the number of authorized shares of common stock from 300,000,000450,000,000 shares to 450,000,000950,000,000 shares.  For adoption of the Company's 2007 Non-Statutory Stock Option Plan, you may vote "For" or "Against" or "Abstain".  For the ratification of the independent Auditors, you may vote “For”"For" or “Against”"Against" or “Abstain”"Abstain" from voting.

The procedures for voting are as follows:

ShareholderEach share of Record: Shares Registered in Your Name

If youour common stock outstanding on the record date is entitled to one vote. We are a shareholderoffering stockholders four methods of record, you may vote in person at the annual meeting or vote by proxy using the enclosed proxy card. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person if you have already voted by proxy.voting:

 ·•ToYou may vote by telephone;
•You may vote over the Internet;
•You may vote in person come toat the annual meeting and we will give you a ballot when you arrive.2008 Annual Meeting; or
 ·To vote using the
•You may request a proxy card simply complete, signfrom us, and dateindicate your vote by completing, signing and dating the card where indicated and by mailing or otherwise returning the card in the enclosed proxy card and return it promptly in theprepaid envelope provided. If you return your signed proxy card to us before the annual meeting, we will vote your shares as you direct.meeting.

Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Nominee

If you are a beneficial owner of shares registered in the name of your broker, bank or other nominee, you should have received a proxy card and voting instructions with these proxy materials from that organization rather than from IDSI. Simply complete and mail the proxy card to ensure that your vote is counted.

A number of brokers and banks are participating in a program provided through ADP Investor Communication Services that offers the means to grant proxies to vote shares by means of the telephone and Internet. If your shares are held in an account with a broker or bank participating in the ADP Investor Communications Services program, you may grant a proxy to vote those shares telephonically by calling the telephone number shown on the instruction form received from your broker or bank, or via the Internet at ADP Investor Communication Services’ web site at (www.proxyvote.com). To vote in person at the meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.

Votes submitted via the Internet or by telephone must be received by 11:59 P.M., Eastern Time, on November 7, 2006; submitting your proxy via the Internet or by telephone will not affect your right to vote in person should you decide to attend the annual meeting.
The telephone and Internet voting procedures are designed to authenticate shareholders’shareholders' identities, to allow shareholders to give their voting instructions and to confirm that shareholders’shareholders' instructions have been recorded properly. Please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies.



HOW MANY VOTES DO I HAVE?

On each matter to be voted upon you haveat the 2008 Annual Meeting, each shareholder is entitled to one vote for each share of common stock you ownowned as of September 7, 2006.November 12, 2008.

WHAT IF I RETURN A PROXY CARD BUT DO NOT MAKE SPECIFIC CHOICES?

If you return a signed and dated proxy card without marking any voting selections, your shares will be voted: (i) “For”"For" the election of all sixtwo nominees for director; (ii) “For”"For" approval of a proposal to amend the Company’sCompany's Articles of Incorporation to increase the number of authorized shares of the Company’sCompany's common stock, no par value, from 300,000,000450,000,000 to 450,000,000950,000,000 and (iii) “For”"For" the ratification of Sherb & Co., LLP as independent auditors of the Company for its fiscal year ending June 30, 2007.2009.  If any other matter is properly presented at the meeting, your proxy (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.

WHO IS PAYING FOR THIS PROXY SOLICITATION?

We will pay the entire cost of the solicitation of proxies including preparation, assembly, printing and mailing of this proxy statement, the proxy and any additional information furnished to shareholders. Copies of solicitation materials will be furnished to banks, brokerage houses, fiduciaries and custodians holding in their names shares of Common Stock beneficially owned by others to forward to such beneficial owners.  Original solicitation of proxies by mail may be supplemented by telephone, facsimile, e-mail, telegram or personal solicitation by directors, officers, or other regular employees of the Company.  No additional compensation will be paid to directors, officers or other regular employees for such services, but our transfer agent Jersey Transfer & Trust Co. will be paid a fee if it renders solicitation services.

WHAT DOES IT MEAN IF I RECEIVE MORE THAN ONE PROXY CARD?

If you receive more than one proxy card, your shares are registered in more than one name or are registered in different accounts.  Please complete, sign and return each proxy card to ensure that all of your shares are voted.

CAN I CHANGE MY VOTE AFTER SUBMITTING MY PROXY?

Yes. You can revoke your proxy at any time before the final vote at the meeting. You may revoke your proxy in any one of three ways:

 ·You may submit another properly completed proxy card with a later date.
 ·
You may send a written notice that you are revoking your proxy to IDSI’sIDSI's Secretary at 65315307 NW 1835thth Court, Plantation, Terrace, Fort Lauderdale, FL 33313.33309.
 ·You may attend the Annual Meeting and vote in person.  Simply attending the meeting will not, by itself, revoke your proxy.




WHEN ARE SHAREHOLDER PROPOSALS DUE FOR NEXT YEAR’SYEAR'S ANNUAL MEETING?

The deadline for submitting a shareholder proposal for inclusion in the Company’sCompany's proxy statement and form of proxy for our next annual meeting of shareholders pursuant to Rule 14a-8 of the Securities and Exchange Commission is June 5, 2007.10, 2009.  Shareholders wishing to submit a proposal or director nomination at the Company’sCompany's next annual meeting must notify the Company of such proposals or nominations in writing to the Secretary of the Company not less than one hundred twenty (120)120 calendar days in advance of the anniversary date of this proxy statement, or by June 5, 2007.10, 2009.

HOW ARE VOTES COUNTED?

Votes will be counted by the inspector of election appointed for the meeting, who will separately count "For" and (with respect to proposals other than the election of directors) "Against" votes, abstentions and broker non-votes.  A "broker non-vote" occurs when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that proposal and has not received instructions with respect to that proposal from the beneficial owner (despite voting on at least one other proposal for which it does have discretionary authority or for which it has received instructions).

Discretionary items are proposals considered routine so that your broker may vote shares held in street name in the absence of your voting instructions.

On non-discretionary items for which you do not give your broker instructions, the shares will be treated as broker non-votes.  Abstentions will be counted towards the vote total for each proposal and will have the same effect as "Against" votes.  Broker non-votes have no effect and will not be counted towards the vote total for any proposal.

HOW MANY VOTES ARE NEEDED TO APPROVE EACH PROPOSAL?

For the election of directors, Proposal No. 1, the two nominees receiving the most "For" votes (among votes properly cast in person or by proxy) will be elected.  Abstentions and broker non-votes are not counted for purposes of the election of a director.

To be approved, Proposal No. 2, to amend the Company's Articles of Incorporation to increase the number of authorized shares of the Company's common stock, no par value, from 450,000,000 to 950,000,000 must receive a "For" vote from the majority of shares present and entitled to vote either in person or by proxy.  If you "Abstain" from voting, it will have the same effect as an "Against" vote.  Broker non-votes will have no effect.

To be approved, Proposal No. 3, the adoption of the Company's 2007 Non-Statutory Stock Option Plan, must receive a "For" vote from the majority of shares present and entitled to vote either in person or by proxy.  If you "Abstain" from voting, it will have the same effect as an "Against" vote.  Broker non-votes will have no effect.



To be approved, Proposal No. 4, the ratification of Sherb & Co., LLP as independent auditors of the Company for its fiscal year ending June 30, 2009, must receive a "For" vote from the majority of shares present and entitled to vote either in person or by proxy.  If you "Abstain" from voting, it will have the same effect as an "Against" vote.  Broker non-votes will have no effect.

WHAT CONSTITUTES A QUORUM?

The presence in person or by proxy of the holders of a majority of the outstanding common stock will constitute a quorum.  A quorum is necessary to transact business at the Annual Meeting.  As of the record date the shareholders held a total of 247,676,633374,264,685 votes.  As such, holders of at least 123,838,317 187,132,343 shares (i.e., a majority) must be present at the meeting, in person or by proxy, to obtain a quorum.

Shares of common stock represented by proxies that reflect abstentions votes withheld or “broker non-votes”"broker non-votes" (i.e., shares held by a broker or nominee which are represented at the Meeting, but with respect to which such broker or nominee hasis not received instructions and does not have discretionempowered to vote on a particular proposal) will be counted as shares that are present and entitled to vote for purposes of determining the presence of a quorum.


HOW MANY VOTES ARE NEEDED TO APPROVE EACH PROPOSAL?

For the election of directors, Proposal No. 1, the six nominees receiving the most “For” votes (among votes properly cast in person or by proxy) will be elected. Votes withheld and broker non-votes are not counted for purposes of the election of a director.

To be approved, Proposal No. 2, to amend the Company’s Articles of Incorporation to increase the number of authorized shares of the Company’s common stock, no par value, from 300,000,000 to 450,000,000, must receive a “For” vote from the majority of shares present and voting either in person or by proxy. If you “Abstain” from voting, it will have the same effect as an “Against” vote. Broker non-votes will have no effect.

To be approved, Proposal No. 3, the ratification of Sherb & Co., LLP as independent auditors of the Company for its fiscal year ending June 30, 2007, must receive a “For” vote from the majority of shares present and voting either in person or by proxy. If you “Abstain” from voting, it will have the same effect as an “Against” vote. Broker non-votes will have no effect.


5


HOW CAN I FIND OUT THE RESULTS OF THE VOTING AT THE ANNUAL MEETING?

Preliminary voting results will be announced at the annual meeting.  Final voting results will be published by the Company in the Company’s quarterly reporta filing of a Current Report on Form 10-Q for8-K within four business days after the first quarter ending September 30, 2006.annual meeting.

HOW CAN I OBTAIN COPIES OF THE COMPANY’SCOMPANY'S ANNUAL REPORT ON FORM 10-K?

The Notice of Annual Meeting, this Proxy Statement and our Annual Report for the fiscal year ended June 30, 2008 have been made available to all shareholders entitled to notice and to vote at the Annual Meeting.  The Annual Report is not incorporated into this Proxy Statement and is not considered proxy-soliciting material.  The Annual Report is posted at the following website addresses: www.imds.com and www.investoreconnect.com.  You may also view and print the annual report on Form 10-K at www.sec.govwww.sec.gov or you may request a copy, free of charge, by written request to the Company, Attn: Secretary at 65315307 NW 1835thth Court, Plantation, Terrace, Fort Lauderdale, FL 33313.33309.



SECURITY OWNERSHIP BY PRINCIPAL SHAREHOLDERSOF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table showsprovides information about the beneficial ownership including shares subject to options, of our common stock as of September 21, 2006 regarding:October 23, 2008. We have listed each person known to us that beneficially owns more than 5% of our outstanding common stock, each of our directors, each of our Named Executive Officers identified in the Summary Compensation Table below, and all directors and executive officers as a group, and the owner of our outstanding $400,000 senior secured convertible debenture.

Beneficial ownership is determined in accordance with the rules of the SEC.  The percentage ownership is based on 374,264,685 shares of common stock outstanding as of October 23, 2008.  In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock underlying options or convertible securities held by that person that are currently exercisable or convertible or exercisable or convertible within 60 days of October 23, 2008 are deemed outstanding.  These shares, however, are not deemed outstanding for the purposes of computing the percentage ownership of any other person.  Except as indicated in the footnotes to this table and as provided pursuant to applicable community property laws, each stockholder named in the table has sole voting and investment power with respect to the shares set forth opposite such stockholder's name.



Name and AddressNumber of Shares Owned% of Outstanding
of Beneficial Owner
Beneficially(1)(2)
Shares of Common Stock
   
Linda B. Grable
  19,660,274(3)
    5.25%
5307 NW 35th Terrace
  
Fort Lauderdale, FL 33309  
   
Allan L. Schwartz
   7,155,520(4)
    1.91%
5307 NW 35th Terrace
  
Fort Lauderdale, FL 33309  
   
Deborah O'Brien
   1,537,000(5)
     0.41%
5307 NW 35th Terrace
  
Fort Lauderdale, FL 33309  
   
Whalehaven Capital Fund Ltd.
  19,656,676(8)
     4.99%(7)
560 Sylvan Avenue   3rd Floor
  
Englewood Cliffs, NJ 07632  
   
   
All officers and directors
 28,352,794(6)
     7.57%
as a group (3 persons)  
   
All beneficial owners  
Listed above (4 persons) 40,632,470  12.56%

(1)·each person that we know of who beneficially owns more than 5% of the outstanding shares of our common stock,
·each current director and executive officer, and
·all executive officers and directors as a group.

Name of
Number of Shares Owned
% of Outstanding
Beneficial Owner
Beneficially (1)(2)
Shares of Common Stock
Linda B. Grable
19,660,274(3)
7.8%
Timothy B. Hansen
1,850,000(4)
0.7%
Allan L. Schwartz
6,988,852(5)
2.8%
Deborah O’Brien
1,035,000(6)
0.4%
Sherman Lazrus
650,000(7)
0.3%
Patrick J. Gorman
1,416,160(8)
0.6%
Edward Rolquin
610,000(7)
0.2%
Jay S. Bendis
665,000(7)
0.3%
All officers and directors
13,215,012(9)
5.3%
as a group (7 persons)
All beneficial owners
32,875,286(10)
13.1%
Listed above (8 persons)


6


(1)
Except as indicated in the footnotes to this table, based on information provided by such persons, the persons named in the table above have sole voting power and investment power with respect to all shares of common stock shown beneficially owned by them.
(2)
Percentage of ownership is based on 252,127,672374,264,685 shares of common stock outstanding as of September 21, 2006October 23, 2008 plus each person’sperson's options that are exercisable within 60 days.  Shares of common stock subject to stock options or convertible securities that are exercisableexercisable/convertible within 60 days as of September 21, 2006October 23, 2008 are deemed outstanding for computing the percentage of that person and the group.
(3)
Based on the last filing of record includesIncludes 3,250,000 shares subject to options and 16,410,274 shares owned by Linda B. Grable. Ms. Grable retired on April 15, 2004.
options.
(4)
Mr. Hansen was issued 100,000 restricted shares pursuant to his employment agreement dated July 8, 2004. Includes 1,750,000 shares subject to options.
(5)
Includes 2,600,0003,100,000 shares subject to options and 9,000 shares owned by the wife of Allan L. Schwartz, Carolyn Schwartz, of which he disclaims beneficial ownership.
(6)(5)Includes 525,0001,027,000 shares subject to options.
(7)(6)Includes 650,000 shares of options owned by Sherman Lazrus, 600,000 shares of options owned by Edward Rolquin and 600,000 shares of options owned by Jay S. Bendis.
(8)Includes 650,000 shares subject to options and 183,356 shares owned by the wife of Patrick J. Gorman, Diana Gorman, of which he disclaims beneficial ownership.
(9)Includes 7,375,0007,377,000 shares subject to options held by Timothy Hansen,Linda Grable, Allan Schwartz and Deborah O’Brien, Sherman Lazrus, Patrick J. Gorman, Edward Rolquin and Jay S. Bendis.O'Brien.  Also includes 9,000 shares owned by the wife of Allan L. Schwartz, Carolyn Schwartz, of which he disclaims beneficial ownership and 183,356ownership.
(7)The shares beneficially owned by the wife of Patrick J. Gorman, Diana Gorman, of which he disclaims beneficial ownership.
(10)Includes allWhalehaven include shares issuable upon conversion of the shares in footnote 9 plus 3,250,000 shares subject to options$400,000 8% Senior Secured Debenture held by Linda B. Grable.Whalehaven, whose conversion price is based on a market formula with a maximum of $.019 per share and a minimum of $.013 per share, shares issuable upon exercise of the Warrant to purchase 22,222,222 shares of common stock  issued to Whalehaven in connection with the Debenture at an exercise price of $.0228 per share and shares issuable to Whalehaven at the conversion price in payment of interest on the Debenture; provided, however, that pursuant to the terms of the Debenture and the Warrant, the total number of shares issuable to Whalehaven pursuant to conversion of the Debenture and/or exercise of the Warrant and/or payment of interest on the Debenture may not exceed that number of shares which would cause Whalehaven to beneficially own 4.99% of the Company's common stock.  This 4.99% limitation may be increased by Whalehaven in its discretion to 9.99% upon 61 days notice to the Company.  In the absence of these beneficial ownership limitations, pursuant to the terms of the Debenture and the Warrant, Whalehaven's beneficial ownership of the Company's common stock would be approximately 44,959,000 shares, or 10.72%.  Whalehaven’s estimated percentage of ownership for this table is calculated based on their 4.99% ownership limitation.  As of October 23, 2008, the maximum number of shares of common stock that Whalehaven could own as a result of a partial conversion/warrant exercise would be 19,656,676 shares.  Thus, the resulting number of common stock outstanding after Whalehaven’s conversion/exercise would be 393,921,361 shares.  Michael Finkelstein and Eric Weisblum have voting and investment control over Whalehaven Capital Fund Ltd.


COMPLIANCE WITH SECTION 16(a) OF THE SECURITIES EXCHANGE ACT OF 1934

Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”"Exchange Act") requires that the Company’sCompany's directors and executive officers, and persons who own more than 10% of a registered class of the Company’sCompany's equity securities, file with the SEC initial reports of ownership and reports of changes in ownership of Common Stock and other equity securities of the Company. Officers, directors and greater than 10% beneficial owners are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.

To the Company’sCompany's knowledge, based solely on a review of the copies of such reports furnished to the Company and written representations that no other reports were required, during the fiscal year ended June 30, 2006,2008, its officers, directors and greater than 10% beneficial owners complied with all applicable Section 16(a) filing requirements.

PROPOSAL 1

ELECTION OF DIRECTORS

Our Board of Directors currently consists of two members: Linda B. Grable (Chairman), and Allan L. Schwartz.  Two directors are to be elected at the 2008 Annual Meeting to hold office until the next annual meeting of stockholders; and until their successors are duly elected and qualified.

Our former independent director, Edward Rolquin, retired on February 27, 2008.  Linda B. Grable was appointed to our Board of Directors in April 2008 to fill one of the vacancies resulting from the April 16, 2008 resignation of our three independent directors:  Jay Bendis; Patrick Gorman; and Sherman Lazrus.  These resignations were tendered to comply with a request by outside funding sources as a condition to such funding.  In the opinion of these funding sources, the benefit to the Company provided by the independent directors was exceeded by their cost and, due to the Company's serious cash shortage, it was in the Company's best interests to accept the resignations of the independent directors and not retain new independent directors until such time as the Company's cash resources improved sufficiently.

From July 2000 until August 2007, when we entered into an agreement for the sale/lease-back of our headquarters facility, Charlton Avenue LLC (“Charlton”) provided all of our necessary funding through the private placement sale of convertible preferred stock with a 9% dividend and common stock through various private equity credit agreements.  Navigator Management, Ltd. is the director of and has sole voting and investment control over Charlton Avenue LLC.  Arlene DeCastro and Gayle Lettsome are Directors of Navigator and control Navigator’s voting on behalf of Charlton.  Upon the resignations of the independent directors, Charlton provided the Company with a new Sixth Private Equity Credit Agreement for up to 15 million dollars.


PROPOSAL 1

ELECTION OF DIRECTORSEach of the two nominees has consented to serve if elected to our Board of Directors.  It is the intention of the persons named as proxies in the accompanying form of proxy to vote all proxies solicited for the two nominees listed below unless the authority to vote is withheld.  If for any reason any nominee shall not become a candidate for election at the 2008 Annual Meeting, an event not now anticipated, the persons named in the proxy will vote for such substitute nominees as are designated by the Board of Directors.  The principal occupation and certain other information concerning the nominees for directors are set forth on the following table and pages.

The following table sets forth certain information concerning nominee directors.

Name*
Age
Position
Year Elected or Appointed
    
Tim Hansen62Chief Executive Officer and Director2004
    
Allan L. Schwartz64Executive Vice-President, Chief1994
  Financial Officer and Director 
    
Sherman Lazrus73Director2002
    
Patrick J. Gorman52Director2003
    
Edward Rolquin77Director2003
    
Jay S. Bendis59Director2003
Name*AgePositionYear Elected or Appointed
    
Linda B. Grable71Chief Executive Officer and Director2008
    
Allan L. Schwartz66Executive Vice-President, Chief1994
  Financial Officer and Director 

Linda Grable and Allan Schwartz is oneare two of theour co-founders and as such may be deemed "promoter" and "parent" as defined in the Rules and Regulations promulgated under the Securities Act.  Directors serve until the next meeting of shareholders.  Officers serve at the pleasure of the Board of Directors.

We have adopted a Code



NOMINEESNOMINEES FOR ELECTION OF DIRECTORS

Tim Hansen

Linda Grable
Tim Hansen
Linda Grable was appointed our Chief Executive Officer and a Director of the Company byin April 2008.  Ms. Grable had previously served as our Chief Executive Officer from August 2001 until April 2004, and, from inception in 1993 until April 2004, had served as Chairman of the Board of Directors in July 2004. Prior to his appointment as CEO and Director of IDSI, Mr. Hansen servedthe Company.  Ms. Grable retired as General Managerour CEO and Chairman of Radiation Management Services, a businessthe Board on April 16, 2004.  Upon the resignations of Cardinal Health, Inc. (NYSE:CAH)our independent directors, Ms. Grable volunteered to come out of Dublin, Ohio from January 2002retirement to July 2004. From August 2001 to January 2002 he servedserve as the President of Syncor Radiation Management in Cleveland, Ohio, a division of Syncor International Corporation (NASDAQ:SCOR) of Woodland Hills, CA. Cardinal Health acquired Syncor in January 2003. From April 2000 to August 2001 Mr. Hansen was a consultant to Inovision, LLC serving as President of Inovision Radiation Measurements in Cleveland, Ohio. He also served as President of Cleaner Foods, Inc. of Cleveland, OHour Chief Executive Officer and a DirectorDirector.  She has played a major role in raising approximately $46 million in debt and equity funding for the research and development of Kliniki St. Paulthe CTLM® device.  She has over 40 years experience in negotiating with banking institutions for funding of Warsaw, Poland from March 2000 to August 2001. From 1982 to 2000 Mr. Hansen held several high-levelboth medical and real estate development businesses.  Ms. Grable has over 25 years of executive positions with Picker International, Inc.experience in the medical device industry, for both sales and marketing in the U.S. and foreign countries.  She is a graduate of Cleveland, Ohio. From 1999 to 2000 he served as President of Picker Medical Systems, a leading manufacturer of diagnostic imaging systems including CTOhio State University and MRI scanners, nuclear medicine imagers and X-Ray systems. Picker International was a wholly owned subsidiary of G.E.C. plc/Marconi Medical Systems with $1.6 billion in annual sales. Philips Medical Systems acquired Marconi in October 2001. Prior to Picker, Mr. Hansen was Vice President of Sales, Service and Marketing for Xonics Medical Systems, Inc. of Des Plaines, IL; National Sales Manager, Manager, Business Planning and Marketing Manager, X-Ray and CT for General Electric Medical Systems of Milwaukee, WI; and Regional Sales Manager for Smith Kline Instruments, a subsidiary of Smith Kline and French. Mr. Hansen holds a Bachelor of Science degreeBA in Economics from the University of Wisconsin-Milwaukee.

Journalism and Marketing.
8

Allan L. Schwartz

Mr. Schwartz is Executive Vice-President and Chief Financial Officer of the Company and is responsible for its financial affairs.  He has a wide range of management, marketing, field engineering, construction, and business development experience.  Prior to joining the Company as a founder in 1993, he developed the Chronometric Trading System for analyzing stock market trends using neural networks and developed pre-engineered homes for export to Belize, Central America for S.E. Enterprises of Miami, Florida.  In 1991 he formed Tron Industries, Inc. for the development of low-voltage neon novelty items and self-contained battery powered portable neon.  He is a graduate of C.W. Post College of Long Island University with a B.S. in Business Administration.  Previous innovations by Mr. Schwartz before relocating to Florida have included the use of motion detection sensors in commercial burglar alarm systems for Tron-Guard Security Systems. Inc. and the use of water reclamation systems with automatic car wash equipment.  Mr. Schwartz has been a Director and Officer of the Company since its inception.

Sherman LazrusTHE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" EACH NOMINEE.

Mr. Lazrus has been a Director since December 2002Due to the resignation on April 16, 2008 of our three remaining independent directors, the following committees have no members and serveswill not be active until such time as a member of the Compensation Committee. On April 15, 2004, thenew independent Board of Directorsmembers are appointed him Co-Chairman of the Board. He has enjoyed a distinguished career with nearly 40 years’ experience in government and private sector health care and health care finance. He is currently a member of Diasys Corporation (DYXC) Board of Directors. From December 1998 to August 2006, Mr. Lazrus served Emergency Filtration Products, Inc., Las Vegas, NV (OTCBB: EMFP) as a Director, Interim Chief Executive Officer and Chairman of the Board of Directors. Mr. Lazrus presently also serves as President of American Medical Capital, a division of American Medical Enterprises, LLC located in Bethesda, Maryland, a financial services and investment banking company specializing in the healthcare industry, a position he has held since 1991. Mr. Lazrus was initially employed with the Federal Government and while at the Department of Health, Education and Welfare in 1964 he was involved with the development of the Medicare and Medicaid Programs and served as the Director of Policy Coordination for the two programs. Also while employed by the Federal Government, Mr. Lazrus served from 1965 to 1966 in the office of the Director of the National Institute of Health and was involved in planning activities in areas involving biomedical research. He later administered the Social Security Administration’s Disability Insurance Research Programs as Director of Program Analysis. Mr. Lazrus’s final Federal Government position encompassed the administration of the military health care system serving as the Deputy Assistant Secretary of Defense from 1974 to 1976. In this position he was the Federal Government’s senior career health official. Mr. Lazrus also served in the State of Maryland’s Governor’s office as Director of the Governor’s Study Group on Vocational Rehabilitation from 1966 to 1968 and later developed a comprehensive human services delivery system for the City of Washington, D.C. from 1968 to 1972. While in the private sector, Mr. Lazrus from 1976 to 1978 was Vice President of American Medical International Inc., a major NYSE hospital corporation, which owned and operated numerous hospitals around the world. The company is now known as Tenet Healthcare Corporation. As a developer Mr. Lazrus was responsible for the development of various Washington D.C. area
office buildings, shopping centers, industrial warehouses and residential communities. Mr. Lazrus attended George Washington University where he received A.A., B.A. and M.B.A. degrees.fill these committees:

Patrick J. Gorman

Mr. Gorman is a Certified Public Accountant. He has been a Director since January 2003 and serves as Chairman of the Audit Committee. On February 26, 2005, the Board of Directors appointed him Co-Chairman of the Board. He is currently the Chief Executive Officer and

9

Chairman of the Board of Directors of Applied Nanoscience Inc., a nanotechnology company based in Hauppauge, New York. From 1991 to 2005 he worked in private practice, serving both publicly traded and privately held companies. Mr. Gorman served as Corporate Tax Manager for Axsys Technologies, Inc. in Deer Park, New York from 1987 to 1990 and Controller/Tax Manager for Computer Associates in Jericho, New York from 1983 to 1986. Prior to joining Computer Associates, he served as Tax Manager with Ernst & Young in Melville, New York and Tax Accountant for Arthur Andersen in New York City. Mr. Gorman holds a MS in Taxation from Long Island University and is a member of the NYSSCPA and the AICPA.

Edward Rolquin

Mr. Rolquin of Naples, Florida, a consultant and retired corporate executive, has been a Director since February 2003 and serves as a member of the Compensation Committee. He has enjoyed a distinguished 48-year career in management, sales and finance with international experience in the medical industry. From 1989 to 1995, he served as a consultant for the Chinese government on various import, export and technology transfer projects. From 1984 to 1992 Mr. Rolquin was the Founder and President of JR Micrographics in Huntington, NY that specialized in medical records management. He has served in a management and consultant capacity while working with major international companies such as Anaconda Copper Mining Company in Chile and El Salvador from 1952 to 1984, Mobil Oil from 1976 to 1984, Cerro Corp., (an international mining company in Peru) from 1962 to 1978, and Esso (Standard Oil) from 1957 to 1968. Mr. Rolquin was responsible for equipping five hospitals for Anaconda, a 100-bed hospital in Chile for Cerro Corp., a 50-bed dispensary for Mobil Oil, and a hospital for Esso.

Jay S. Bendis

Mr. Bendis of Akron, Ohio, has been a Director since February 2003 and serves as a member of the Audit Committee and is Chairman of the Compensation Committee. On April 15, 2004, the Board of Directors appointed him Co-Chairman of the Board. He has over 30 years experience in sales and marketing and is currently President of Transfer Technology Consultants, Akron, OH, where he specializes in transferring new product concepts through to commercialization working with established and start-up companies in both domestic and international markets. Mr. Bendis is also President and CEO of Clinical Analysis Corp. which has developed a portable, handheld chemistry analyzer for patient point of care testing. He was the Managing Partner of the Crystal Corridor Group, Hudson, OH, which works with Kent State University’s Liquid Crystal Institute in facilitating liquid crystal technology. From 1995 to 2000, Mr. Bendis was Vice President of Sales and Marketing and a Director of American Bio Medica Corp. a public company in Kinderhook, NY, which develops and markets on-site drug abuse diagnostic kits. From 1993 to 1999, he was the President and co-founder of Emerging Technology Systems, Akron, OH, which is a research and development company specializing in developing new concept medical devices. From 1990 to 1992, he was a co-founder and Vice President of Sales and Marketing and a Director for Scientific Imaging Instruments of Trumbull, CT. From 1985 to 1990, he served as National Sales Manager of the XANAR Laser Corp., Colorado Springs, CO, a division of Johnson & Johnson, where he directed its national sales force and developed its marketing strategy for integrating high power lasers into the hospital market. From 1979 to 1984, he was the Sales and Marketing Manager for the IVAC Corp., San Diego, CA, a division of Eli Lilly Corp. and has had sales and management experiences with XEROX and A.M. International. He has also served as a member of the Edison BioTechnology Center Advisory Council for the State of Ohio. Mr. Bendis presently serves as a director of Aduromed Corp. (GDVC) and also serves on the Boards of several private companies. He earned his B.A. in Marketing/Management from Kent State University.

10


AUDIT COMMITTEE

The Board of Directors elected Patrick J. Gorman as Chairman of the Audit Committee in February 2003.Committee.  In addition, the Board hashad determined that Mr. Gorman iswas an “audit"audit committee financial expert,”" as defined under new SEC regulations, who is independent of management of the Company.  Jay S. Bendis also servesserved as a member of the Audit Committee.

12
COMPENSATION COMMITTEETable of Contents


Compensation Committee
The Board of Directors elected Jay S. Bendis as Chairman of the Compensation Committee in May 2003.Committee.  Sherman Lazrus and Edward Rolquin also serveserved as members of the Compensation Committee.

NOMINATING AND CORPORATE GOVERNANCE COMMITTEE

Nominating and Corporate Governance Committee
The Board of Directors elected Sherman Lazrus as Chairman of the Nominating and Corporate Governance Committee in October 2004.Committee.  Jay S. Bendis, Patrick J. Gorman and Edward Rolquin also serveserved as members of the Nominating and Corporate Governance Committee. All the members


Compliance with Section 16(a) of the NominatingSecurities Exchange Act of 1934
Section 16(a) of the Securities Exchange Act of 1934 requires our directors and Corporate Governance Committee are independent directors.executive officers, and persons who own more than ten percent of our common stock, to file with the SEC initial reports of ownership and reports of changes in ownership, furnishing us with copies of all Section 16(a) forms they file.  To the best of our knowledge, based solely on review of the copies of such reports furnished to us, all Section 16(a) filing requirements applicable to our officers and directors were complied with during the year ended June 30, 2008.


COMPENSATIONCOMPENSATION OF DIRECTORSDIRECTORS-FISCAL 2008

EachAs of October 1, 2004 the annual base rate for director who iscompensation was increased from $8,000 to $12,000 for each non-employee director payable quarterly, and annual option grants of 200,000 shares vesting 50,000 shares per quarter.  We have not anpaid and will not pay separate compensation for Board service by employee directors.  New directors received stock options of 100,000 shares for the first year of service and 200,000 shares per year for the second year and each year thereafter.  Our Board of Directors consisted of two Co-Chairmen, one of whom was Chairman of the Company receives a quarterly retainerAudit Committee and the other Chairman of $3,000 andthe Compensation Committee.  The annual base rate for the Co-Chairmen was increased on October 1, 2004 from $8,000 to $20,000.  No additional base compensation was paid for serving on the Audit Committee or Compensation Committee.  Board members were paid $800 per diem fees for days in which a Boardboard meeting iswas attended or a non-employee board member iswas otherwise required to visit the Company or spend a significant amount of a day working on Company matters. matters ("workshop days").  We reimbursed travel expenses for attending board meetings and expenses associated with workshop days.

The Co-Chairmen receive a quarterly retainerfollowing table sets forth certain information regarding the compensation of $5,000 each, which includes their servicesour directors (other than directors who are also Named Executive Officers) for the fiscal year ended June 30, 2008.



              Change in       
              Pension Value       
              and       
              Nonqualified       
  Fees Earned        Non-Equity  Deferred       
  or Paid  Stock  Option  Incentive Plan  Compensation  All other    
Name and in Cash  Awards  Awards  Compensation  Earnings  Compensation  Total 
Principal Position ($)  ($)  ($)  ($)  ($)  ($)  ($) 
Jay Bendis(1)
  36,079   -   15,467   -   -   -   51,546 
                             
Patrick Gorman(2)
  34,479   -   13,333   -   -   -   47,812 
                             
Sherman Lazrus(3)
  20,527   -   12,400   -   -   -   32,927 
                             
Edward Rolquin(4)
  17,333   -   7,467   -   -   -   24,800 

(1)Mr. Bendis had 1,100,000 stock options outstanding as of June 30, 2008 all of which are fully vested.  Mr. Bendis resigned from the Board on April 16, 2008.
(2)Mr. Gorman had 1,100,000 stock options outstanding as of June 30, 2008 all of which are fully vested.  Mr. Gorman resigned from the Board on April 16, 2008.
(3)Mr. Lazrus had 1,100,000 stock options outstanding as of June 30, 2008 all of which are fully vested.  Mr. Lazrus resigned from the Board on April 16, 2008.
(4)Mr. Rolquin had 900,000 stock options outstanding as of June 30, 2008 all of which are fully vested.  Mr. Rolquin retired from the Board on February 27, 2008.

Compensation Discussion and Analysis
This section describes the material elements of compensation awarded to, earned by or paid to the individuals who served as Chairman ofour former chief executive officer, our current chief executive officer, our executive vice president & chief financial officer, and our senior vice president during fiscal 2008.  These individuals are listed in the Audit"Summary Compensation Table" below and are referred to as the "Named Executive Officers".

Our executive compensation programs were determined and proposed by our Compensation Committee and Compensation Committee, respectively. Non-employee directors are also reimbursedapproved by our Board of Directors, for travel expenses. In October 2004,so long as the Compensation Committee madewas in existence.  None of the Named Executive Officers was a proposalmember of the Compensation Committee or otherwise had any role in determining the compensation of other Named Executive Officers, although the Compensation Committee did consider the recommendations of our CEO in setting compensation levels for our other executive officers.  Our Compensation Committee was comprised of three out of our four independent directors.  On February 27, 2008, Edward Rolquin, a member of the Compensation Committee, announced his retirement from the Board of Directors.  On April 16, 2008, we received and accepted the resignations of our three outside directors:  Jay Bendis; Patrick Gorman; and Sherman Lazrus.  Mr. Gorman was not a member of the Compensation Committee.  These resignations were tendered to raisecomply with a request by outside funding sources as a condition to such funding.  Upon their resignations, the daily workshop fee from $600Board of Directors assumed the duties of the Compensation Committee.



All references below to $800 per day,the Compensation Committee refer to raise the quarterly retainersBoard of directors from $2,000Directors since April 16, 2008, except where the context requires otherwise.


Executive Compensation Program Objectives and Overview.

The Compensation Committee conducts an annual review of our executive compensation programs to $3,000, and to raiseensure that:

·the program is designed to achieve our goals of promoting financial and operational success by attracting, motivating and facilitating the retention of key employees with outstanding talent and ability; and
·the program adequately rewards performance which is tied to creating stockholder value.
·Our current executive compensation program is based on two components, which are designed to be consistent with our compensation philosophy: (1) base salary and (2) grants of stock options.

In structuring executive compensation packages, the Co-Chairman’s quarterly retainers from $2,000 to $5,000. They further agreed that any new directors appointedCompensation Committee considers how each component promotes retention and/or motivates performance by the Board or electedexecutive.  Base salaries, perquisites and personal benefits, and severance and other termination benefits are primarily intended to attract and retain highly qualified executives. We believe that in order to attract and retain top executives, we need to provide them with compensation levels that reward their continued productive service.  At the present time the Compensation Committee does not award annual incentive bonuses while we are in the development stage but does believe that such annual awards do motivate executive officers to achieve specific strategies and operating objectives and also help us to attract and retain top executives.  The Compensation Committee has discussed the implementation of long-term equity incentives which are primarily intended to align executive officers' long-term interests with stockholders' long-term interests, although we believe they also play a role in helping us to attract and retain top executives.  Currently, stock option grants are the part of our executive compensation program designed to reward performance and thus the creation of stockholder value.

We view our current executive compensation program as one in which the individual components combine together to create a total compensation package for each executive officer that we believe achieves our compensation objectives.  In determining our current executive compensation program and the amounts of compensation for each component of our program, the Compensation Committee evaluates the current executive compensation data for companies in our industry.  The Compensation Committee believes that our current executive compensation program is appropriate based on the evaluation of the compensation paid by companies in our industry.


Current Executive Compensation Program Elements.

Base Salaries
Salaries for our three executive officers are reviewed by the shareholdersCompensation Committee on an annual basis.  During fiscal 2008, the cash salaries paid to Linda Grable, Tim Hansen, Allan Schwartz and Deborah O'Brien were $30,000, $150,000, $185,802, and $139,588, respectively.


During fiscal 2007, the cash salaries paid to Tim Hansen, Allan Schwartz and Deborah O'Brien were $240,810, $191,048, and $130,769, respectively.  During fiscal 2006, the cash salaries paid to Tim Hansen, Allan Schwartz and Deborah O'Brien were $210,000, $185,000, and $112,169, respectively.

Annual Incentive Bonuses
The Compensation Committee may elect to award incentive bonuses as part of total compensation to executive officers who have rendered services during the year that exceed those normally required or anticipated or who have achieved specific targeted objectives with regard to sales performance, financial performance, inventory efficiencies and other criteria which may be established from time to time.  These bonuses are intended to reflect the Compensation Committee's determination to reward any executive who, through extraordinary effort, has substantially benefited the Company and its stockholders during the year.  During fiscal 2008, no annual incentive bonuses were paid.

Stock Option Grants
Our policy is that the long-term compensation of our Named Executive Officers and other executive officers should be directly linked to the value provided to stockholders.  Therefore, we have periodically made grants of stock options to provide further incentives to our executives to increase stockholder value.  During fiscal 2008, the stock option grants made to Linda Grable, Tim Hansen, Allan Schwartz and Deborah O'Brien were 1,000,000, 0, 250,000 and 250,000, respectively.  During fiscal 2007, the stock option grants made to Tim Hansen, Allan Schwartz and Deborah O'Brien were 3,000,000, 250,000 and 250,000, respectively.  During fiscal 2006, the stock option grants made to Tim Hansen, Allan Schwartz and Deborah O'Brien were 0, 100,000 and 0, respectively.  Stock options are granted with an exercise price that is equal to the closing price of our common stock on the grant date.  Thus, the recipients will realize value on their stock options if our stockholders realize value on their shares.  The Compensation Committee bases its grants of stock options to executives on a number of factors, including:

·the executive's position with us and total compensation package;
·the executive's performance of his or her individual responsibilities; and
·the executive's contribution to the success of our financial performance.

Compensation Committee Report

The following statement shall receive 100,000 options, $3,000 quarterly retainernot be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, and $800 per day for workshop days. The Board voted in favorshall not otherwise be deemed filed under either of these acts.

Due to the resignation of our independent directors, the Compensation Committee did not review and discuss with management the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K.




Compensation Committee Interlocks and Insider Participation

No member of the proposal. The increased director compensation became effectiveCompensation Committee was an officer or employee of our Company during the prior year or was formerly an officer of our Company.  During the fiscal year ended June 30, 2008, none of our executive officers served on October 1, 2004. In December 2003, the Compensation Committee of any other entity, any of whose directors or executive officers served either on our Board voted to increase the amount of options that non-employee directors are eligible to receive from 100,000 to 200,000 shares per year, vesting at 50,000 shares per quarter of service to the Company. The option structure will take effectDirectors or on each non-employee director’s respective anniversary date. The option price will be at the Fair Market Value (FMV) on each respective director’s anniversary date.our Compensation Committee.


BOARD MEETINGS AND COMMITTEES

The Board of Directors met fivefour times during the fiscal year ended June 30, 2006.2008.  All directors were present for all board and committee meetings during fiscal 2006.2008.  During fiscal 2000, the Board established an Audit Committee and a Compensation Committee.  During fiscal 2004, the Board established a Nominating and Governance Committee.

The Audit Committee serves to monitor the financial controls and reporting of the Company.  The Compensation Committee has the responsibility to review and make recommendations to the Board of Directors regarding executive compensation and stock option matters.  The Nominating and Governance Committee has the responsibility to review the

11

structure and composition of the Board of Directors and to consider the qualifications of and recommend all nominees for directors and to develop a set of corporate governance principles for the Company.  There are no employees or employee directors who serve on either the Compensation, Audit or Nominating and Governance Committees.

CODE OF BUSINESS CONDUCT AND ETHICS

Pursuant to Section 406 of the Sarbanes-Oxley Act of 2002, on May 7, 2003 the Board of Directors adopted a Code of Business Conduct, which applies to all officers, employees and directors of the Company.  The Board also adopted a Code of Ethics, which applies to its Principal Executive Officer (CEO) and Senior Financial Officers.  The Code of Ethics was adopted on May 7, 2003 and filed as Exhibit 14.1 with our Form 10-KSB for the fiscal year ended June 30, 2003.  If the Company makes any substantive amendment of, or grants any waiver to, the Code of Business Conduct and Ethics, the Company will disclose the nature of such amendment of waiver in a current report on form 8-K.  On November 7, 2007, our Board of Directors approved an amendment to our Code of Conduct as recommended by our Corporate Governance Committee and disclosed the amendment waiver in a current report on form 8-K.


SHAREHOLDER COMMUNICATIONS WITH OUR BOARD OF DIRECTORS

The Company maintains contact information by e-mail on its website under the heading “Contact IDSI”"Contact IDSI".  By following the Contact IDSI link, a shareholder will be given access to the Company’sCompany's telephone number and mailing address as well as a link for providing e-mail correspondence to Investor Relations.  Also provided arewere the e-mail addresses of the non-employee directors.directors before their respective resignations.



REQUIRED VOTE

For the election of directors, Proposal No. 1, the sixtwo nominees receiving the most “For”"For" votes (among votes properly cast in person or by proxy) will be elected.  Abstentions and broker non-votes are not counted for purposes of the election of a director.

THE BOARD OF DIRECTORS OF THE COMPANY RECOMMENDS A VOTE “FOR”"FOR" THE ELECTION OF THE NOMINEES NAMED ABOVE. PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE VOTED FOR THE NAMED NOMINEES UNLESS INSTRUCTIONS ARE GIVEN TO THE CONTRARY.

12


MANAGEMENTMANAGEMENT

DIRECTORS AND EXECUTIVE OFFICERS

The following table sets forth certain information concerning each of our executive officers.  The relevant information concerning our current directors is set forth in “Proposal"Proposal 1 -– Election of Directors”Directors" above.

Name*
Age
Position
Year Elected or Appointed
Tim Hansen62Chief Executive Officer and Director2004
    
Allan L. Schwartz64Executive Vice-President, Chief1994
  Financial Officer and Director 
    
Deborah O’Brien42Senior Vice-President2003
NameAgePositionYear Elected or Appointed
Linda B. Grable71Chief Executive Officer and Director2008
    
Allan L. Schwartz66Executive Vice-President, Chief1994
  Financial Officer and Director 
    
Deborah O'Brien44Senior Vice-President2003

See information concerning Mr. HansenMs. Grable and Mr. Schwartz under “Proposal"Proposal 1 -– Election of Directors”Directors" above.


Deborah O’BrienO'Brien

Ms. Deborah O’BrienO'Brien was appointed Senior Vice President on September 15, 2003.  She currently is responsible for FDA regulatory matters, Clinical trials, Clinical Training, Marketing, Service, and Investor Relations. Since joiningMs. O'Brien has been employed at IDSI in 1995,since 1995.  During her tenure, she has held the positions of Director of Investor Relations, Vice President of Corporate Communications and most recently, since September 2001, Vice President of Business Development.  Her responsibilities have included developing and executing a strategic corporate communications campaign, managing internal communications, outside public relations, marketing, and clinical applications.  In addition, Ms. O’BrienO'Brien was directly responsible for the development and establishment of consumer and industry awareness of our CTLM® System via a media outreach which targeted industry publications, national network television, radio, nationally-circulated publications and high traffic internet sites.  As Vice President of Business Development, she was closely involved with various regulatory and marketing projects and played an integral role in the development and preparation of our PMA Application.  She also supervised and managed the collection of clinical


data for the PMA process.  Prior to joining IDSI, she worked for seven years in the financial arena, managing investor accounts, and in the medical device industry, marketing medical equipment.  Ms. O’BrienO'Brien began her career in the mortgage loan industry as an account executive with Citibank.


13

EXECUTIVEEXECUTIVE COMPENSATION

The following table sets forth the compensation awarded to, earned by or paid to our Chief Executive Officer, former Chief Executive Officer, Executive Vice President & CFO and other executive officersSenior Vice President for services rendered to us during fiscal 2006, 20052008, 2007 and 2004.2006.  No other person during these years, who served as one of our executive officers, had a total annual salary and bonus in excess of $100,000.  Also, see “Stock"Stock Option Plan-Option Grants in Last Fiscal Year”Year".

SUMMARY COMPENSATION TABLE – FISCAL 2008
 
                                                                                SUMMARY COMPENSATION TABLE
                  Change in       
                  Pension Value       
                  and       
                  Nonqualified       
               Non-Equity  Deferred       
         Stock  Option  Incentive Plan  Compensation  All other    
Name and  Salary  Bonus  Awards  Awards  Compensation  Earnings  Compensation  Total 
Principal PositionYear ($)  ($)  ($)  
($)(6)
  ($)  ($)  ($)  ($) 
Linda B. Grable2008  30,000   -   -   1,667   -   -   -   31,667 
CEO and COB(1)(2)
2007  -   -   -   -   -   -   -   - 
 2006  128,333   -   -   -   -   -   -   128,333 
                                  
                                  
Timothy B. Hansen2008  150,000   -   -   66,311   -   -   -   216,311 
CEO and Director(1),(3)
2007  240,810   -   -   241,960   -   -   -   482,770 
 2006  210,000   -   -   194,965   -   -   -   404,965 
                                  
                                  
Allan L. Schwartz2008  185,802   -   -   12,500   -   -   -   198,302 
Exec V.P.,CFO and Director(1),(4)
2007  191,048   -   -   18,500   -   -   -   209,548 
 2006  185,000   -   -   20,000   -   -   -   205,000 
                                  
                                  
Deborah O'Brien2008  139,588   -   -   16,018   -   -   -   155,606 
Senior Vice- President(1),(5)
2007  130,769   -   -   35,609   -   -   -   166,378 
 2006  112,169   -   -   76,800   -   -   -   188,969 

 
Annual Compensation
Long-Term Compensation
      
Name & Principal
  
Other Annual
Restricted
Shares Underlying
Position
Fiscal Year
Salary
Compensation(5)
Stock Awards
Options Granted
Linda B. Grable (1)
2004$347,594$11,500  
 2005$280,000   
 2006$128,333   
      
Timothy B. Hansen,2005$194,423 $38,0003,000,000
CEO and Director(2)
2006$210,000   
      
Allan L. Schwartz,2004$184,219$11,500 500,000
Exec. V.P., CFO and2005$199,784  500,000
Director (3)
2006$185,000  100,000
      
Edward R. Horton2004$114,400$5,750  
COO(6)
2005$123,675  175,000
 2006$50,320   
      
Deborah O’Brien2004$92,542$11,500 302,000
Senior V. Pres. (4)
2005$99,750   
 2006$112,169   


(1)All Named Executive Officers receive reimbursement for auto expense in the amount of $500 per month.
(2)On April 16, 2008, Ms. Grable our former CEOcame out of retirement and Director, retiredrejoined the company as Chairman of the Board and CEO.  Previously, on April 15, 2004.2004 Ms Grable retired.  Under her retirement agreement Ms.Ms Grable was entitled to receive her $280,000 annual salary through December 15, 2005.  Salary recorded for f/y 2004 includes $47,704 in accrued wages payable as of 6/30/02 to Linda B. Grable as heir to the estate of Richard J. Grable and $19,890 in accrued wages payable as of 6/30/02 to Linda B. Grable.2006 was $128,333.
(2)(3)On December 27, 2007, Mr. Hansen commenced employment on July 26, 2004. Restricted stock awardsretired from the Company effective January 1, 2008.  Salary recorded for f/y 2005 include $38,0002008 includes base salary of non-cash compensation for sign-on bonus in restricted stock.$130,000 plus $19,500 vacation pay.  On January 17, 2007, Mr. Hansen signed a new employment agreement that increased his salary to $260,000.  On July 26, 2006, Mr. Hansen received a 7% cost of living increase based on the prior two years' inflation, raising his salary to $226,000.
(3)(4)Salary recorded for f/y 2008 includes base salary of $179,142 plus $6,660 vacation pay.  From April 1, 2008 through June 30, 2008, Mr. Schwartz indeferred $12,025 (25%) of his salary until a time where the Company secures additional financing.  Salary recorded for f/y 20052007 includes base salary of $185,000 plus $5,179 as additional wages while serving as Interim CEO and $9,605$6,048 vacation pay.
(5)Salary recorded for f/y 2008 includes base salary of $135,342 plus $4,246 vacation pay.  Salary recorded for f/y 20042007 includes base salary of $154,329$125,000 plus $19,890$5,769 vacation pay.  Ms. O'Brien began receiving auto expense in accrued wages payable as of 6/30/02 and $10,000 additional wages while serving as Interim CEO.
(4)Ms. O’Brien was appointed Senior Vice President on September 15, 2003. Salary recorded for f/y 2005 includes base salary of $95,000 plus $4,750 vacation pay.2006.  Salary recorded for f/y 2006 includes base salary of $95,000 and $17,169 as additional pay for duties previously performed by our former COO, Mr. Horton.
(5)Other Annual Compensation reflects non-cash compensation for holiday stock bonuses which was previously included in the total amount of salaries paid to executive officers in 2004.
(6)Mr. Horton voluntarily resigned on October 31, 2005.Amount listed represents the dollar amount we recognized for financial reporting purposes under FASB No. 123R, "Share Based Payment".




Employment Agreements

At a special meeting of the Board of Directors held on August 28, 2001 the Board, with Mrs. Grable abstaining, voted to grant a death benefit of one year’s salary ($286,225) to Richard Grable’s beneficiary in recognition of his services as a co-founder, CEO and inventor of the CTLM®. On April 15, 2004, we paid the balance due of this death benefit to Linda Grable, as beneficiary of Richard Grable.

On August 15, 2001, we entered into a three-year employment agreement with Edward Horton, our Chief Operating Officer at an annual salary of $110,000. The COO was also granted 500,000 incentive stock options at an exercise price of $.77 per share, the fair market value at the date of the grant, which vested ratably over the three-year period. Upon the expiration of his employment agreement on August 15, 2004, we entered into a one-year employment agreement with Mr. Horton at an annual salary of $125,000. He was also granted 175,000 non-statutory stock options at an exercise price of $.28, the fair market value at the date of the grant, which will vest at the end of the one-year period. Mr. Horton voluntarily resigned on October 31, 2005.

On December 1, 2001, we entered into a new three-year employment agreement with Linda Grable. Under this agreement, Ms. Grable received an annual base salary of $280,000. Ms. Grable received incentive options to purchase up to an aggregate of 2,250,000 shares of our common stock at an exercise price of $.60 per share. The incentive stock options were scheduled to vest at 750,000 shares per year starting December 1, 2002. In addition, she received a car allowance of $500 per month. On April 15, 2004, Ms. Grable retired as CEO and Chairman of the Board. As part of her Retirement Agreement, the Board of Directors agreed to pay out the remainder of her employment agreement and continue coverage of her health insurance through its expiration on December 15, 2005. The total amount due for the unexpired term of her agreement was $466,667 (based on her salary of $280,000 per year). Payments were made on our normal payroll schedule. The payments continued through December 15, 2005, at which time all obligations were satisfied.

On September 15, 2003, we entered into a three-year employment agreement with Deborah O’Brien, our Senior Vice-President at an annual salary of $95,000. The Senior Vice-President was also granted 302,000 incentive stock options at an exercise price of $1.13 per share, the fair market value at the date of the grant, which will vest ratably over the three-year period. On September 12, 2006, we entered into a one-year employment agreement with Ms. O’Brien at an annual salary of $125,000. The Senior Vice-President was also granted a $25,000 performance bonus opportunity and 250,000 non-statutory stock options at an exercise price of $.114 per share, the fair market value at the date of the grant, which will vest in one year.

On July 8, 2004, we entered into a three-year employment agreement with Timothy Hansen, our new Chief Executive Officer, commencing on July 26, 2004 at an annual salary of $210,000 and appointed him a Director of the Company. Mr. Hansen was granted 1,500,000 non-statutory stock options at an exercise price of $.38, the fair market value at the date of the grant, which will vest over the three-year period in accordance with the table below:

Date of Vesting
No. of Option Shares
July 8, 2005500,000
January 8, 2006250,000
July 8, 2006250,000
January 8, 2007250,000
July 8, 2007250,000


15


Mr. Hansen also received 100,000 restricted shares of our common stock. He also receives a $500 car allowance per month and received pre-approved living expenses for a three-month period and moving expenses.

On February 23, 2005, Mr. Hansen was granted an additional 1,500,000 non-statutory stock options at an exercise price of $.32, the fair market value at the date of the grant, which will vest over the three-year period in accordance with the table below:

Date of Vesting
No. of Option Shares
February 23, 2006500,000
August 23, 2006250,000
February 23, 2007250,000
August 23, 2007250,000
February 23, 2008250,000

On August 30, 2004 Allan L. Schwartz, our Executive Vice-President and Chief Financial Officer, entered into a one-year Employment Extension Agreement, which provided for an annual salary of $185,000 and options to purchase up to an aggregate of 500,000 shares of our common stock at an exercise price of $.30 per share, in accordance with our 2004 Non-Statutory Stock Option Plan. These options vested on August 30, 2005. On September 12, 2005, we entered into a one-year employment agreement effective August 30, 2005 with Mr. Schwartz, at an annual salary of $185,000. Mr. Schwartz was also granted 100,000 non-statutory stock options at an exercise price of $.20 per share, the fair market value at the date of the grant, which will vest on August 30, 2006. On September 12, 2006, we entered into a one-year employment agreement effective August 30, 2006 with Mr. Schwartz at an annual salary of $185,000. Mr. Schwartz was also granted 250,000 non-statutory stock options at an exercise price of $.114 per share, the fair market value at the date of the grant, which will vest on August 30, 2007.OUTSTANDING EQUITY AWARDS AT FISCAL 2008 YEAR-END

The following table sets forth certain information with regard toconcerning unexercised options outstanding for each of our Named Executive Officers at June 30, 2008.
                          
  Option Awards Stock Awards 
                        Equity 
                        Incentive 
        Equity            Equity Incentive  Plan Awards: 
        Incentive            Plan Awards:  Market or 
        Plan Awards:         Market  Number of  Payout Value 
  Number of  Number of  Number of      Number of  Value of  Unearned  of Unearned 
  Securities  Securities  Securities      Shares or  Shares or  Shares, Units  Shares, Units 
  Underlying  Underlying  Underlying      Units of  Units of  or Other  or Other 
  Unexercised  Unexercised  Unexercised  Option   Stock That  Stock That  Rights That  Rights That 
  Options  Options  Unearned  Exercise Option Have Not  Have Not  Have Not  Have Not 
   (#)   (#)  Options  Price Expiration Vested  Vested  Vested  Vested 
Name Exercisable  Unexercisable   (#)  ($) Date  (#)  ($)   (#)  ($) 
Linda B. Grable   500,000    -    -   $2.85�� 8/30/2010                
CEO and Chairman   500,000    -      -   $ 0.77         8/30/2011                
of the Board(1)     2,250,000    -    -  $ 0.60         12/1/2011                
   -    1,000,000    -   $ 0.045        4/16/2018                
                                  
                                  
Timothy B. Hansen  1,250,000   -   -  $0.38 1/1/2011  -   -   -   - 
CEO and Director(2)
  1,000,000   -   -  $0.32 1/1/2011                
   1,000,000   -   -  $0.09 1/1/2011                
                                  
                                  
Allan L. Schwartz   500,000   -   -  $2.85  8/30/2010  -   -   -   - 
Exec V.P., CFO and  500,000   -   -  $0.77  8/30/2011                
Director(3)
  500,000   -   -  $0.30 8/30/2012                
  500,000   -   -  $1.21 8/30/2013                
   500,000   -   -  $0.30 8/30/2014                
   100,000   -   -  $0.20 9/12/2015                
   250,000   -   -  $0.11 9/12/2016                
       250,000       $ 0.058        8/30/2017                
                                  
                                  
Deborah O'Brien  200,000   -   -  $0.56  10/25/2011  -   -   -   - 
Senior Vice-  25,000   -   -  $0.50  2/02/2012                
President(4)   301,000   1,000   -  $1.13 9/15/2013                
   250,000   -   -  $0.11 9/12/2016                
       250,000       $ 0.084        9/15/2017                
(1)Ms. Grable had 4,250,000 stock options outstanding as of June 30, 2008 of which 3,250,000 are fully vested.
(2)Mr. Hansen had 3,750,000 stock options outstanding as of June 30, 2008 of which 3,750,000 are fully vested.
(3)Mr. Schwartz had 3,100,000 stock options outstanding as of June 30, 2008 of which 2,850,000 are fully vested.
(4)Ms. O'Brien had 1,027,000 stock options outstanding as of June 30, 2008 of which 776,000 are fully vested.





OPTION EXERCISES AND STOCK VESTED - FISCAL 2008

The following table sets forth information concerning each exercise of stock options for each of our Named Executive Officers during the Options granted by the Company to executive management for the fiscal year ended June 30, 2006. Timothy Hansen, Allan L. Schwartz, Edward Horton (resigned) and Deborah O’Brien did not exercise any options during fiscal 2006.2008.


 
Option AwardsStock Awards
Number ofNumber of
Shares AcquiredValue RealizedShares AcquiredValue Realized
on Exerciseon Exerciseon Vestingon Vesting
Name(#)($)(#)($)
Linda B. Grable
CEO and
Chairman of the
Board
Timothy B. Hansen
Former CEO and----
Director
Allan L. Schwartz
Exec V.P., CFO
and Director----
Deborah O'Brien
Senior Vice-President----


Stock Option Grants in Last Fiscal YearPlans

 
No. of
    
 
Securities
% of Total
   
 
Underlying
Options Granted
Exercise of
Market Price
 
 
Options
to Employees In
Base Price
On Date of
Expiration
Name
Granted
Fiscal Year
($/Share)
Grant
Date
Allan L. Schwartz100,0007.5%$.20     $.20   9/12/2015


Stock Option Plans

Our 1995 Stock Option Plan was approved by our Board of Directors and adopted by the shareholders at the March 1995 annual meeting.  The plan provided for the granting, exercising and issuing of incentive options pursuant to Internal Revenue Code, Section 422.

On August 30, 1999, we established an equity incentive plan.  The shareholders had to approve this plan within one year.  The maximum number of shares that could be granted under this plan

16

was15,000,000 shares of common stock and 5,000,000 shares of preferred stock.  The series, rights and preferences of the preferred stock were to be determined by our Board of Directors.  This plan also included any stock available for future stock rights under our 1995 Stock Option Plan.  On January 3, 2000 the Board of Directors decided to replace this equity incentive plan and adopted our 2000 Non-Statutory Stock Option Plan so as to provide a critical long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company.  On May 10, 2000 our shareholders approved the 2000 Non-Statutory Stock Option Plan, which was replaced with our 2002 Incentive and Non-Statutory Stock Option Plan approved by our shareholders on March 13, 2002.  Our Board of Directors has direct responsibility for the administration of the plan.



On February 4, 2004, the Board of Directors adopted our 2004 Non-Statutory Stock Option Plan (the “2004 Plan”"2004 Plan"), which was adopted by the shareholders on March 24, 2004 at our annual meeting to provide a long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company and its subsidiaries.  The maximum number of options that may be granted under the 2004 Plan shall be options to purchase 8,432,392 shares of Common Stock (5% of our issued and outstanding common stock as of February 4, 2004).

Options may be granted under the 2004 Plan for up to 10 years after the date of the 2004 Plan.  The 2004 Non-Statutory Stock Plan replaced the 2002 Incentive and Non-Statutory Stock Option Plan.

On August 24, 2005, the Board Of Directors resolved that the Company’sCompany's 1995, 2000, 2002 and 2004 Stock Option Plans and Stock Options Agreements that were entered into pursuant to these plans, be amended to increase the post-termination exercise period following the termination of the Optionee’sOptionee's employment/directorship or in the event of change of control of the Company, to be three years from the date of termination or change of control, subject to those options that were vested as of the date of termination or change of control and subject to the original term of the option, which ever time is less.

On July 26, 2007, the Board of Directors adopted the Company's 2007 Non-Statutory Stock Option Plan (the "2007 Plan").  The 2007 Plan was re-adopted by the Board on April 16, 2008.  The Plan must be adopted by the shareholders at the annual meeting which must occur within one year of the Board's adoption of the 2007 Plan.  The 2007 Plan will provide a long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company.  The maximum number of options that may be granted under the 2007 Plan shall be options to purchase 15,693,358 shares of Common Stock (5% of our issued and outstanding common stock as of July 26, 2007).  Options may be granted under the 2007 Plan for up to 10 years after the date of the 2007 Plan.  The 2007 Non-Statutory Stock Plan replaced the 2004 Non-Statutory Stock Option Plan.




PROPOSALPROPOSAL 2

INCREASE IN THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK

The Company'sOur Articles of Incorporation currently authorize the issuance of 300,000,000450,000,000 shares of common stock, and 2,000,000 shares of Preferred Stock, no par value.  On August 28, 2006,1, 2008, the Board of Directors unanimously approved a proposal to amend our Articles of Incorporation to increase the number of authorized shares of common stock from 300,000,000450,000,000 shares to 450,000,000950,000,000 shares.  As of September 21, 2006, 252,127,672the record date of November 12, 2008, 374,264,685 shares of common stock were outstanding and 16,817,335outstanding; 23,797,936 shares of common stock were reserved for issuance upon the exercise of outstanding stock options.options; 24,888,888 were reserved for issuance upon the exercise of outstanding warrants, and 22,736,846 were reserved for issuance upon conversion of a $400,000 outstanding 8% senior secured convertible debenture issued to Whalehaven Capital Fund Limited ("Whalehaven") in August 2008.  No shares of preferred stock have been issued to date.  As of November 13, 2008, 374,264,685 shares of common stock were outstanding.

We have faced many challenges over our 14-year history.  The development of an innovative medical imaging technology is a complicated, time consuming and very expensive process.  Since inception, substantially all of our necessary funding has come from the proceeds of the sale of common stock, convertible preferred stock and convertible debentures.  The convertible securities were all converted into common stock.  Since April 1999, we have issued to Charlton a total of 292,304,895 shares of common stock through conversion of $13,410,000 face amount of our preferred stock and debentures purchased by Charlton and through $41,694,758 in purchases under all of our private equity lines.  Since January 2001 we have primarily used a series of private equity credit agreements with Charlton Avenue, LLC, an institutional investor, to raise the capital necessary to fund the Company's operations.  The use of private equity credit agreements is dilutive as the investor sells our shares into the market.  Since January 2001, we have drawn an aggregate of $41,694,758 in gross proceeds from our equity credit lines with Charlton and have issued 248,676,012 shares as a result of those draws.  As of the date of this proxy statement, we have issued all 50,000,000 shares that were registered on our Form S-1 registration statement which went effective on May 28, 2008, for use with our Sixth Private Equity Credit Agreement with Charlton.  Hypothetically, if we drew down the entire $13,977,500 remaining available under the Sixth Private Equity Credit Agreement, we would be required to issue approximately 577,582,645 shares based on the closing bid price of our common stock on November 13, 2008 of $.026 per share.

Over the course of the last several years we asked for, and subsequently received, shareholder approval to increase the number of authorized IDSI common stock shares so that we would be able to utilize our private equity credit agreements with Charlton to fund the Company.  We had hoped that the shares previously authorized would be sufficient to meet our funding needs, but with the unforeseen delays in our PMA process, and without more cash from commercialization, which has continued to be slower than expected, and given that our stock price has declined more than anticipated, we will require additional authorized shares to fund IDSI in its normal course of business and to provide reasonable strategic reserves.



The additional shares of common stock would have rights identical to the shares of common stock currently outstanding or reserved for issuance.  Holders of theour common stock of the Company are entitled to one vote for each share of common stock held and are entitled to receive such dividends as may be declared from time to time by the Board of Directors.  In addition, upon a liquidation, dissolution or winding up of the Company,IDSI, the holders of common stock are entitled to receive a pro rata portion of theour net assets of the Company which remain, if any, after the payment of any debts, obligations and liquidation preferences. There are no preemptive rights associated with any of the Company'sour stock.

The Board of Directors believebelieved that the availability of the proposed amount of additional authorized shares of common stock will provide the Companyus with the flexibility to issue common stock in connection with equity financing, stock options, conversion of debentures, warrants, possible future acquisitions, stock splits or other appropriate general corporate purposes.  If the proposal is approved, the additional shares will be available for issuance without further authorization of the shareholders, unless such action is required by applicable law or the rules of the NASDAQ OTC Bulletin Board or any subsequent exchange on which theour stock of the Company may be listed.  At this time, the Company haswe have no present plans, understandings or agreements for the issuance or use of the proposed additional shares of common stock, except for (i) sales of the stock to Charlton Avenue LLC (“Charlton”("Charlton") pursuant to our private equity agreement with Charlton. WeCharlton, under which we expect to make those sales from time to time at a price equal to 93% of the then market price based on the formula set forth in the agreement.agreement, and (ii) shares issuable in connection with the conversion of the Whalehaven debenture and exercise of warrants issued to Whalehaven and our placement agent in connection with our Securities Purchase Agreement with Whalehaven dated August 1, 2008.

The issuance of additional shares of common stock or the rights to acquire such shares would have the effect of diluting the Company'sour earnings per share in the event that we become profitable and will dilute the voting power of current shareholders who do not acquire sufficient additional shares to maintain their percentage of share ownership. Additional shares of common stock could also be used by the CompanyIDSI to oppose a hostile takeover attempt; however, the Board of Directors presently knows of no such attempt to obtain control of the Company.

RECOMMENDATION OF THE BOARD OF DIRECTORS

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR”"FOR" THE PROPOSAL TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 300,000,000450,000,000 SHARES TO 450,000,000950,000,000 SHARES.




PROPOSAL 3

CONSIDER AND ACT UPON A PROPOSAL 3TO ADOPT THE COMPANY'S 2007 NON-STATUTORY STOCK OPTION PLAN

The Board of Directors on July 26, 2007 adopted the Company's 2007 Non-Statutory Stock Option Plan (the "2007 Plan") so as to provide a critical long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company and its subsidiaries.  The Board of Directors believes that the Company's policy of granting stock options to such persons will continue to provide it with a critical advantage in attracting and retaining qualified candidates.  In addition, the 2007 Plan is intended to provide the Company with maximum flexibility to compensate plan participants.  It is expected that such flexibility will be an integral part of the Company's policy to encourage employees, non-employee directors, consultants, attorneys and advisors to focus on the long-term growth of stockholder value.  The Board of Directors believes that important advantages to the Company are gained by an option program such as the 2007 Plan which includes incentives for motivating employees of the Company, while at the same time promoting a closer identity of interest between employees, non-employee directors, consultants, attorneys and advisors on the one hand, and the stockholders on the other.

The principal terms of the 2007 Plan are summarized below and a copy of the 2007 Plan is annexed to this Proxy Statement as Exhibit A.  The summary of the 2007 Plan set forth below is not intended to be a complete description thereof and such summary is qualified in its entirety by the actual text of the 2007 Plan to which reference is made.

Summary Description of the Imaging Diagnostic Systems, Inc. 2007 Non-Statutory Stock Option Plan

The purposes of the 2007 Plan attached hereto as Exhibit A, is to provide directors, officers and employees of, consultants, attorneys and advisors to the Company and its subsidiaries with additional incentives by increasing their ownership interest in the Company.  Directors, officers and other employees of the Company and its subsidiaries are eligible to participate in the 2007 Plan.  Options in the form of Non-Statutory Stock Options ("NSO") may also be granted to directors who are not employed by the Company and consultants, attorneys and advisors to the Company providing valuable services to the Company and its subsidiaries.  In addition, individuals who have agreed to become an employee of, director of or an attorney, consultant or advisor to the Company and/or its subsidiaries are eligible for option grants, conditional in each case on actual employment, directorship or attorney, advisor and/or consultant status.  The 2007 Plan provides for the issuance of NSO's only, which are not intended to qualify as "incentive stock options" within the meaning of Section 422 of the Internal Revenue Code, as amended.

The maximum number of options that may be granted under the 2007 Plan shall be options to purchase 15,693,358 shares of Common Stock (4.99% of the Company's issued and outstanding common stock as of July 26, 2007).



Options may be granted under the 2007 Plan for up to 10 years after the date of the 2007 Plan.  The Board of Directors of the Company or a Compensation Committee will administer the 2007 Plan with the discretion generally to determine the terms of any option grant, including the number of option shares, exercise price, term, vesting schedule and the post-termination exercise period.  Notwithstanding this discretion (i) the term of any option may not exceed 10 years and (ii) an option will terminate as follows: (a) if such termination is on account of termination of employment for any reason other than death, without cause, such options shall terminate one year thereafter; (b) if such termination is on account of death, such options shall terminate 15 months thereafter; and (c) if such termination is for cause (as determined by the Board of Directors and/or Compensation Committee), such options shall terminate immediately.  Unless otherwise determined by the Board of Directors or Compensation Committee, the exercise price per share of Common Stock subject to an option shall be equal to no less than 100% of the fair market value of the Common Stock on the date such option is granted.  No NSO shall be assignable or otherwise transferable except by will or the laws of descent and distribution or except as permitted in accordance with SEC Release No.33-7646 as effective April 7, 1999 and in particular that portion thereof which expands upon transferability as is contained in Article III entitled "Transferable Options and Proxy Reporting" as indicated in Section A, 1 through 4 inclusive and Section B thereof.

The 2007 Plan may be amended, altered, suspended, discontinued or terminated by the Board of Directors without further stockholder approval, unless such approval is required by law or regulation or under the rules of the stock exchange or automated quotation system on which the Common Stock is then listed or quoted.  Thus, stockholder approval will not necessarily be required for amendments which might increase the cost of the 2007 Plan or broaden eligibility except that no amendment or alteration to the Plan shall be made without the approval of stockholders which would (a) increase the total number of shares reserved for the purposes of the Plan or decrease the exercise price (except as provided in Article X of the 2007 Plan relating to recapitalizations and mergers) or change the classes of persons eligible to participate in the Plan or (b) extend the exercise period or (c) materially increase the benefits accruing to 2007 Plan participants or (d) materially modify Plan participation eligibility requirements or (e) extend the expiration date of the Plan.  Unless otherwise indicated the 2007 Plan will remain in effect until terminated by the Board of Directors.

Federal Tax Consequences

The following is a brief description of the federal income tax consequences generally arising with respect to options that may be granted under the 2007 Plan.  This discussion is only intended for the information of stockholders considering how to vote at the Annual Meeting, and not as tax guidance to individuals who participate in the 2007 Plan.

Because tax results may vary due to individual circumstances, each participant in the 2007 Plan is urged to consult his personal tax adviser with respect to the tax consequences of the exercise of an option or the sale of stock received upon the exercise thereof, especially with respect to the effect of state tax laws.



No income is recognized by an optionee when a non-qualified stock option is granted.  Except as described below, upon exercise of a nonqualified stock option, an optionee is treated as having received ordinary income at the time of exercise in an amount equal to the difference between the option price paid and the then fair market value of the Common Stock acquired.  The Company is entitled to a deduction at the same time and in a corresponding amount.  The optionee's basis in the Common Stock acquired upon exercise of a nonqualified stock option is equal to the option price plus the amount of ordinary income recognized, and any gain or loss thereafter recognized upon disposition of the Common Stock is treated as capital gain or loss.

Stock acquired by "insiders' (i.e., officers, directors or persons holding 10% or more of the stock of the Company who are subject to the restrictions on short-swing trading imposed by Section 16(b) of the Securities Exchange Act of 1934) upon exercise of nonqualified stock options constitutes "restricted property" and, unless the optionee elects otherwise, the recognition of income upon exercise is deferred to the date upon which the stock acquired upon exercise may first be sold without incurring Section 16(b) liability (generally six months after grant of the option).  If such an optionee does not elect to recognize income upon exercise, the insider will realize ordinary income in an amount equal to the difference between the option price and the fair market value on the date the stock may first be sold without incurring Section 16(b) liability.

Vote Required for Approval

The affirmative vote of a majority of the outstanding shares of the Common Stock present in persons or represented by Proxy at the Annual Meeting and entitled to vote is required to approve the adoption of the Stock Option Plan.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ADOPTION OF THE 2007 NON-STATUTORY STOCK OPTION PLAN




PROPOSAL 4

RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS

The Board of Directors has appointed Sherb & Co., LLP, with offices in New York and Florida, to be our independent auditors for the fiscal year ending June 30, 2007.2009.  Representatives of the firm are expected to be present at the Annual Meeting, will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

There will be presented at the Annual Meeting a proposal for the ratification of this selection, which the Board of Directors believes is advisable and in the best interests of the shareholders.  If the selection of Sherb & Co., LLP is not ratified, the matter of selection of independent auditors will be considered by the Board of Directors.

The proposed fees from Sherb & Co., LLP are $49,000$57,000 for annual audit, quarterly reviews and internal control audit and $2,000$2,500 for tax services.

THE BOARD OF DIRECTORS OF THE COMPANY RECOMMENDS A VOTE “FOR”"FOR" THE RATIFICATION OF SHERB & CO., LLP AS THE COMPANY’SCOMPANY'S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING JUNE 30, 2007.2009.


DEADLINEDEADLINE FOR RECEIPT OF SHAREHOLDER PROPOSALS

The Company anticipates that the next Annual Meeting will be held on or about October 31, 2007November 18, 2009 and that the proxy materials for that Annual Meeting are expected to be mailed around September 26, 2007.October 10, 2009.  If any shareholder wishes a proposal to be considered for inclusion in the next Proxy Statement, this material must be received by the Secretary no later than June 5, 2007.10, 2009.

OTHER MATTERS

The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to take such action on such matters in accordance with their best judgment.

 By Order of the Board of Directors
  
 
/s/ Allan L. Schwartz
 Allan L. Schwartz, Secretary



APPENDIXAPPENDIX A

IMAGING DIAGNOSTIC SYSTEMS, INC.
PROXY SOLICITED BY THE BOARD OF DIRECTORS
FOR THE ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD ON NOVEMBER 8, 2006DECEMBER 29, 2008

The undersigned hereby appoints TimothyLinda B. HansenGrable and Allan L. Schwartz and each of them, as attorneys-in-fact and proxies of the undersigned, with full power of substitution, to vote all of the shares of stock of Imaging Diagnostic Systems, Inc. which the undersigned may be entitled to vote at the Annual Meeting of Shareholders of Imaging Diagnostic Systems, Inc. to be held at the Company’s offices,Sheraton Suites Cypress Creek, located at 6531555 NW 1862ndth Court, Plantation, Street, Fort Lauderdale, Florida, on November 8, 2006December 29, 2008 at 9:00 A.M., local time, and at any and all continuations and adjournments thereof, with all powers that the undersigned would possess if personally sent, upon and in respect of the following matters and in accordance with the following instructions, with discretionary authority as to any and all other matters that may properly come before the meeting.

(Continued, and to be signed on the other side)

Please mark your votes as this [X]

THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED BY THE SHAREHOLDER.  IF NO DIRECTION IS GIVEN WHEN THE DULY EXECUTED PROXY IS RETURNED, SUCH SHARES WILL BE VOTED “FOR”"FOR" THE NOMINEES NAMED HEREON, “FOR”"FOR" THE PROPOSED AMENDMENT TO THE COMPANY’SCOMPANY'S ARTICLES OF INCORPORATION TO INCREASE AUTHORIZED COMMON STOCK, "FOR" THE ADOPTION OF THE 2007 NON-STATUTORY STOCK OPTION PLAN, AND “FOR”"FOR" THE RATIFICATION OF SHERB & CO., LLP AS INDEPENDENT AUDITORS.  THE SHARES WILL BE VOTED AT THE DISCRETION OF THE PROXIES AND ATTORNEYS-IN-FACT ON THE TRANSACTION OF SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING AND ANY ADJOURNMENT THEREOF.

FOR
PROPOSAL 1: To elect sixtwo directors to hold office until the next Annual Meeting
of Shareholders.

  FORWITHHOLDWITHOLD
Nominees:TimothyLinda B. HansenGrable[   ][   ]
 Allan L. Schwartz[   ][   ]
Sherman Lazrus[ ][ ]
Patrick J. Gorman[ ][ ]
Edward Rolquin[ ][ ]
Jay S. Bendis[ ][ ]

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR"“FOR” THE ELECTION OF ALL OF THE NOMINEES LISTED ABOVE.




FOR    
PROPOSAL 2: To approve an amendment FORAGAINSTABSTAIN
to the Articles of Incorporation to increase    
the number of authorized shares of common [   ][   ][   ]
stock from 300,000,000450,000,000 shares to 450,000,000950,000,000    
shares.    

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR"“FOR” THE INCREASE IN THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK.

FOR
PROPOSAL 3: To adopt the Company'sFORAGAINSTABSTAIN
2007 Non-Statutory Stock Option Plan
[   ][   ][   ]

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ADOPTION OF THE 2007 NON-STATUTORY STOCK OPTION PLAN.

FOR    
PROPOSAL 3:4: To ratify selection of FORAGAINSTABSTAIN
Sherb & Co., LLP, as independent    
auditors of the Company for its fiscal [   ][   ][   ]
Year ending June 30, 2007.2009.    

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR"“FOR” THE RATIFICATION OF THE INDEPENDENT AUDITORS

I PLAN TO ATTEND THE MEETING[   ]
ADMISSION TO ANNUAL MEETING WILL BE BY TICKET ONLY TO SHAREHOLDERS OF RECORD ON RECORD DATE.  ADMISSION TICKETS WILL BE MAILED TO THE ADDRESS ENTERED BELOW:

Name:______________________________________________________

Street Address:_______________________________________________

City:_______________________________State:____Zip:_____________

Please sign exactly as your name appears hereon. If the stock is registered in the names of two or more persons, each must sign. Executors, administrators, trustees, guardians and attorney-in-fact should add their titles. If the signer is a corporation, please give full corporate name and have a duly authorized officer, stating title. If the signer is a partnership, please sign in partnership name by authorized person.


Signature____________________________________ Date________________

PLEASE VOTE, DATE AND PROMPTLY RETURN THIS PROXY IN THE ENCLOSED RETURN ENVELOPE, WHICH IS POSTAGE PREPAID IF MAILED IN THE UNITED STATES.

If you are attending the Annual Meeting and wish to ask questions at the conclusion of the meeting, you may submit your questions in writing via e-mail to questions@imds.com on or before November 1, 2006.December 8, 2008.




EXHIBIT A

In accordance with shareholders’shareholders' approval of a proposal to amend the Company’sCompany's Articles of Incorporation to increase the number of authorized shares of the Company’sCompany's common stock, no par value, from 300,000,000450,000,000 to 450,000,000950,000,000 duly executed by a majority of the votes cast by the shareholders of Imaging Diagnostic Systems, Inc. entitled to vote thereon, and ratification of such action by the Company’sCompany's Board of Directors, the Company’sCompany's Articles of Incorporation are hereby Amended as follows:


The name of the corporation is IMAGING DIAGNOSTIC SYSTEMS, INC.

ARTICLE III CAPITAL STOCK

The maximum number of shares of capital stock that this corporation is authorized to have outstanding at any one time is 452,000,000 (FOUR952,000,000 (NINE HUNDRED FIFTY-TWO MILLION) shares, no par value.  The 452,000,000952,000,000 shares of no par value capital stock of the Corporation shall be designated as follows:

 ·450,000,000950,000,000 common shares
   
 ·2,000,000 Preferred Shares, the rights, and preferences of which are to be designated by the Company’sCompany's Board of Directors.


Except as amended above the remainder of the Company’sCompany's Articles of Incorporation shall remain unchanged, and are hereby ratified and confirmed.

The foregoing Amendment to the Articles of Incorporation was duly adopted on November 8, 2006December 29, 2008 by a majority vote of the holders of the Corporation's common stock, no par value, no Preferred Shares being outstanding, and approved by a sufficient number of votes pursuant to the Florida Statutes.

ATTESTED TO:
IMAGING DIAGNOSTIC SYSTEMS, INC.
  
  
By: _________________________________Name:_____________________________
  
  
 Title:______________________________
  
  
By: _________________________________Name:_____________________________
  
  
 Title:______________________________


EXHIBIT B

(Previously Filed as Exhibit 10.77 to our Form 10-K for the fy June 30, 2007 filed on September 13, 2007.)

IMAGING DIAGNOSTIC SYSTEMS, INC.


2007 NON-STATUTORY STOCK OPTION PLAN


I.  
PURPOSE OF THE PLAN.

This 2007 Non-Statutory Stock Option Plan (the "Plan") is intended to promote the interests of Imaging Diagnostic Systems, Inc., a Florida corporation (the "Company"), by providing (i) key employees (including officers and directors) of the Company (or its parent or subsidiary corporations) who contribute to the management, growth and financial success of the Company (or its parent or subsidiary corporations) and (ii) consultants and other independent advisors who provide valuable services to the Company (or its parent or subsidiary corporations) with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Company as an incentive for them to remain in the service of the Company (or its parent or subsidiary corporations).

For purposes of the Plan, the following provisions shall be applicable in determining the parent and subsidiary corporations of the Company:

(A)Any corporation (other than the Company) in an unbroken chain of corporations ending with the Company shall be considered to be a parent of the Company, provided each such corporation in the unbroken chain (other than the Company) owns, at the time of the determination, stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

(B)Each corporation (other than the Company) in an unbroken chain of corporations beginning with the Company shall be considered to be a subsidiary of the Company, provided each such corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

II.  
DEFINITIONS.

As used herein, the following definitions shall apply:

"Board" shall mean the Committee, if one has been appointed, or the Board of Directors of the Company if no Committee is appointed.

"Code" shall mean the Internal Revenue Code of 1986, as amended.



"Committee" shall mean the Committee appointed by the Board in accordance with paragraph (A) of Section IV of the Plan, if one is appointed, or the Board if no committee is appointed.
"Common Stock" shall mean the no par value common stock of the Company.

"Company" shall mean Imaging Diagnostic Systems, Inc., a Florida corporation.

"Consultant" shall mean any person who is engaged by the Company or any Parent or Subsidiary to render consulting services and is compensated for such consulting services, but does not include a director of the Company who is compensated for services as a director only with the payment of a director's fee by the Company.

"Continuous Status as an Employee" shall mean the absence of any interruption or termination of service as an Employee.  Continuous Status as an Employee shall not be considered interrupted in the case of sick leave, military leave, or any other leave of absence approved by the Board; provided that such leave is for a period of not more than 90 days or reemployment upon the expiration of such leave is guaranteed by contract or statute.

"Employee" shall mean any person, including officers and directors, employed by the Company or any Parent or Subsidiary of the Company.  The payment of a director's fee by the Company shall not be sufficient to create "employment" by the Company.

"Non-Employee Director" shall mean a director who:

(i)Is not currently an officer (as defined in Section 16a-1(f) of the Securities Exchange Act of 1934, as amended) of the Company or a Parent or Subsidiary of the Company, or otherwise currently employed by the Company or a Parent or Subsidiary of the Company; and/or

(ii)Does not receive compensation, either directly or indirectly, from the Company or a Parent or Subsidiary of the Company, for services rendered as a Consultant or in any capacity other than as a director, except for an amount that does not exceed the dollar amount for which disclosure would be required pursuant to Item 404(a) of Regulation S-K adopted by the United States Securities and Exchange Commission; and/or

(iii)Does not possess an interest in any other transaction and is not engaged in any business relationship for which disclosure would be required pursuant to Rule 404(a) or Rule 404(b) of Regulation S-K adopted by the United States Securities and Exchange Commission.

"Non-Statutory Stock Option" shall mean an Option granted under this Plan.

"Option" shall mean a Non-Statutory Stock Option.  No option granted under this Plan shall be treated as an incentive stock option under Section 422 of the Code.



"Optioned Stock" shall mean the Common Stock subject to an Option.

"Optionee" shall mean an Employee, Director or Consultant who is granted an Option.
"Parent" shall mean a "parent corporation," whether now or hereafter existing, as defined in Section 424(e) of the Code.

"Plan" shall mean this 2007 Non-Statutory Stock Option Plan.

"Share" shall mean a share of the Common Stock of the Company, as adjusted in accordance with Section X of the Plan.

"Service" shall mean service to the Company as an Employee, Consultant or Director.

"Stock Option Agreement" shall mean the agreement to be entered into between the Company and each Optionee which shall set forth the terms and conditions of each Option granted to each Optionee, including the number of Shares underlying such Option and the exercise price of each Option granted to such Optionee under such agreement.

"Subsidiary" shall mean a "subsidiary corporation," whether now or hereafter existing, as defined in Section 424(f) of the Code.

III.  
STOCK SUBJECT TO THE PLAN.

(A)Subject to the provisions of Section IX of the Plan, the maximum aggregate number of Shares which may be optioned and sold under the Plan, is 15,693,358 shares of Common Stock.  Shares of the Common Stock shall be available for issuance under the Plan and may be drawn from the Company's authorized but unissued shares of Common Stock, from reacquired shares of Common Stock, including shares repurchased by the Company on the open market, or from Common Stock otherwise reserved pursuant to this Plan.  If an Option should expire or become unexercisable for any reason without having been exercised in full, the unpurchased Shares which were subject thereto shall, unless the Plan shall have been terminated, become available for future grant under the Plan.

(B)Should one or more outstanding options under this Plan expire or terminate for any reason prior to exercise in full, then the Shares subject to the portion of each option not so exercised shall be available for subsequent option grant under the Plan.  Shares issued under the Plan shall not be available for subsequent option grant under the Plan.  In addition, should the exercise price of an outstanding option under the Plan be paid with shares of Common Stock, then the number of shares of Common Stock available for issuance under the Plan shall be reduced by the gross number of shares for which the option is exercised, and not by the net number of shares of Common Stock actually issued to the holder of such option.

(C)In the event any change is made to the Common Stock issuable under the Plan by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the


Company's receipt of consideration, appropriate adjustments shall be made to the number and/or class of securities and price per share in effect under each outstanding option under the Plan.  Such adjustments to the outstanding options are to be effected in a manner which shall preclude the enlargement or dilution of rights and benefits under such options. The adjustments determined by the Committee shall be final, binding and conclusive.

(D)Common Stock issuable under the Plan may be subject to such restrictions on transfer, repurchase rights or other restrictions as may be determined by the Committee.

IV.  
ADMINISTRATION OF THE PLAN.

(A)Procedure. The Plan shall be administered by the Board or a Committee appointed by the Board consisting of two or more Non-Employee Directors to administer the Plan on behalf of the Board, subject to such terms and conditions as the Board may prescribe.  Once appointed, the Committee shall continue to serve until otherwise directed by the Board (which for purposes of this paragraph (A) of this Section IV shall be the Board of Directors of the Company).  From time to time the Board may increase the size of the Committee and appoint additional members thereof, remove members (with or without cause) and appoint new members in substitution therefore, fill vacancies however caused, or remove all members of the Committee and thereafter directly administer the Plan.  Members of the Board who are granted, or have been granted, Options may vote on any matters affecting the administration of the Plan or the grant of any Options pursuant to the Plan.

(B)Powers of the Board. Subject to the provisions of the Plan, the Board shall have the authority, in its discretion:

(i)  To grant Non-Statutory Stock Options as provided and identified in a separate written Stock Option Agreement to each Optionee granted such Option or Options under the Plan; provided, however, that in no event shall a Non-Statutory Stock Option granted to any Optionee under a single Stock Option Agreement be subject to a "tandem" exercise arrangement such that the exercise of one such Option affects the Optionee's right to exercise the other Option granted under such Stock Option Agreement;

(ii)  To determine, upon review of relevant information and in accordance with Section VII (A) of the Plan, the fair market value of the Common Stock;

(iii)  To determine the exercise price per Share of Options to be granted, which exercise price shall be determined in accordance with Section VII of the Plan;

(iv)  To determine the Employees or other persons to whom, and the time or times at which, Options shall be granted and the number of Shares to be represented by each Option;

(v)  To interpret the Plan;



(vi)  To prescribe, amend and rescind rules and regulations relating to the Plan;

(vii)  To determine the terms and provisions of each Option granted (which need not be identical) and, with the consent of the holder thereof, modify or amend each Option;

(viii)  To accelerate or defer (with the consent of the Optionee) the exercise date of any Option, consistent with the provisions of Section VII of the Plan;

(ix)  To reduce the exercise price of any Option to the then current Fair Market Value if the Fair Market Value of the Common Stock covered by such Option shall have declined since the date the Option Right was granted;

(x)  To authorize any person to execute on behalf of the Company any instrument required to effectuate the grant of an Option previously granted by the Board; and

(xi)  To make all other determinations deemed necessary or advisable for the administration of the Plan.

(C)Effect of Board's Decision. All decisions, determinations and interpretations of the Board shall be final and binding on all Optionees and any other permissible holders of any Options granted under the Plan.

V.  ELIGIBILITY

(A)Persons Eligible. Options may be granted to any Employee, Director or Consultant selected by the Board; provided however, that a Consultant shall be ineligible to receive Options hereunder in consideration of services relating to the offer or sale of securities in a capital raising transaction or the direct or indirect promotion or maintenance of a market for the Company's securities.  An Employee who is also a director of the Company, its Parent or a Subsidiary, shall be treated as an Employee for purposes of this Section V.  An Employee or other person who has been granted an Option may, if he is otherwise eligible, be granted an additional Option or Options.

(B)No Effect on Relationship. The Plan shall not confer upon any Optionee any right with respect to continuation of employment, directorship, consultancy or any other relationship with the Company nor shall it interfere in any way with his/her right or the Company's right to terminate his/her employment, directorship, consultancy or any other relationship at any time.

VI.  
TERM OF PLAN.

The Plan becomes effective on the date the Plan is approved by the Board, provided that it is approved by the shareholders of the Company within 12 months following Board approval.  It


shall continue in effect until a date that is 10 years after such Board approval, unless sooner terminated under Section XI of the Plan.

VII.  
TERMS & CONDITIONS OF THE OPTIONS.

Options granted pursuant to the Plan shall be authorized by action of the Committee and will be Non-Statutory Options.  Each granted option shall be evidenced by one or more instruments in the form approved by the Committee; provided, however, that each such instrument shall comply with the terms and conditions specified below.

(A)Option Price.  The Committee shall fix the option price per share.  In no event, however, shall it be less than 100% of the fair market value per share of Common Stock on the date of the option grant.  The option price shall become immediately due upon exercise of the option and, subject to the instrument evidencing the grant, shall be payable in one of the following alternative forms specified below:

(i)  full payment in cash or check drawn to the Company's order;

(ii)  full payment in shares of Common Stock held for at least six months and valued at fair market value on the Exercise Date (as such term is defined below);

(iii)  full payment in a combination of shares of Common Stock held for at least six months and valued at fair market value on the Exercise Date and cash or check; or

(iv)  full payment through a broker-dealer sale and remittance procedure provided that sale of the Optioned Stock is permitted as a result of an effective registration statement under the Securities Act of 1933, as amended, and compliance with all applicable securities laws, pursuant to which the Optionee (i) shall provide irrevocable written instructions to a Company-designated brokerage firm to effect the immediate sale of the purchased shares and remit to the Company, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate option price payable for the purchased shares plus all applicable Federal and State income and employment taxes required to be withheld by the Company in connection with such purchase and (ii) shall provide written directives to the Company to deliver the certificates for the purchased shares directly to such brokerage firm in order to complete the sale transaction.

For purposes of this Section VII, the Exercise Date shall be the date on which written notice of the option exercise is delivered to the Company.  Except to the extent the sale and remittance procedure is utilized in connection with the exercise of the option, payment of the option price for the purchased shares must accompany such notice.



The fair market value per share of Common Stock on any relevant date under the Plan shall be determined in accordance with the following provisions:

(1)If the Common Stock is not at the time listed or admitted to trading on any national stock exchange but is traded on the NASDAQ National Market, the fair market value shall be the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers on the NASDAQ National Market System or any successor system.  If there is no reported closing selling price for the Common Stock on the date in question, then the closing selling price on the last preceding date for which such quotation exists shall be determinative of fair market value.

(2)If the Common Stock is at the time listed or admitted to trading on any national stock exchange, then the fair market value shall be the closing selling price per share of Common Stock on the date in question on the stock exchange determined by the Committee to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange.  If there is no reported sale of Common Stock on such exchange on the date in question, then the fair market value shall be the closing selling price on the exchange on the last preceding date for which such quotation exists.

(3)If the Common Stock is quoted on the NASDAQ Small Cap Market, or any similar system of automated dissemination of quotations of securities process in common use, the fair market value shall be the mean between the closing bid and asked quotations for the Common Stock on such date.

(4)If neither clause (1), (2) or (3) is applicable, then the fair market value shall be the mean between the closing bid and asked quotations for the Common Stock as reported by the National Quotation Bureau, Inc., if at least two securities dealers have inserted both bid and asked quotations for Common Stock on at least five of the ten preceding business days.

(5)If neither clause (1), (2), (3) or (4) is applicable, then the fair market value shall be determined by the Committee using such criteria as it deems appropriate.

(B)Term and Exercise of Options. Each Option shall be exercisable at such time or times, during such period and subject to such conditions, including performance criteria with respect to the Company and Optionee, as may be determined by the Committee and set forth in the stock option agreement evidencing the grant.  No such option, however, shall have a maximum term in excess of 10 years from the grant date.  An Option may not be exercised for a fraction of a share.  During the lifetime of the Optionee, the Option shall be exercisable only by the Optionee and shall not be assignable or transferable by the Optionee otherwise than by will or by the laws of descent and distribution following the Optionee's death.



(C)Termination of Service.  Except to the extent otherwise provided pursuant to Section VII (C)(v) below, the following provisions shall govern the exercise period applicable to any outstanding Options under the Plan which are held by the Optionee at the time of his or her cessation of Service:

(i)Should the Optionee cease Service for any reason other than death (including permanent disability as defined in Section 22(e)(3) of the Code) while holding one or more outstanding Options under the Plan, then none of those Options shall (except to the extent otherwise provided pursuant to Section VII (C)(v)) remain exercisable beyond the limited post-Service period designated by the Committee at the time of the Option grant and set forth in the Option agreement.

(ii)During the term of the Option if the Optionee was at the time of his death an Employee and had been in Continuous Status as an Employee or Consultant since the date of grant of the Option, the Option may be exercised, at any time within 12 months following the date of death, by the Optionee's estate or by a person who acquired the right to exercise the Option by bequest or inheritance, but only to the extent of the right to exercise that would have accrued had the Optionee continued living and remained in Continuous Status as an Employee 12 months after the date of death.

(iii)Under no circumstances, however, shall any such Option be exercisable after the specified expiration date of the Option term.

(iv)During the limited post-Service exercise period, the Option may not be exercised for more than the number of shares for which the Option is exercisable on the date of the Optionee's cessation of Service.  Upon the expiration of such limited exercise period or (if earlier) upon the expiration of the Option term, the Option shall terminate and cease to be exercisable.  However, upon the Optionee's cessation of Service, each outstanding Option at the time held by the Optionee shall immediately terminate and cease to be outstanding with respect to any shares for which the Option is not otherwise at that time exercisable or in which the Optionee is not otherwise vested.

(v)Should (i) the Optionee's Service be terminated for misconduct (including, but not limited to, any act of dishonesty, willful misconduct, fraud or embezzlement) or (ii) the Optionee make any unauthorized use or disclosure of confidential information or trade secrets of the Company or its Parent or Subsidiary, then in any such event all outstanding Options held by the Optionee under this Plan shall terminate immediately and cease to be exercisable.

The Committee shall have complete discretion, exercisable either at the time the Option is granted or at any time while the Option remains outstanding, to permit one or more Options held by the Optionee under this Plan to be exercised, during the limited period of exercisability provided under subparagraph (i) above, not only with respect to the number of shares for which each such Option is exercisable at the time of the Optionee's cessation of Service but also with respect to one or more subsequent installments for which the Option would


otherwise have become exercisable during such limited period had such cessation of Service not occurred.

For purposes of the foregoing provisions of this section (and for all other purposes under the Plan):

(1)  The Optionee shall (except to the extent otherwise specifically provided in the applicable Option agreement) be deemed to remain in the Service of the Company for so long as such individual renders services on a periodic basis to the Company (or any Parent or Subsidiary) in the capacity of an Employee, a Non-Employee Director or a Consultant.

(2)  The Optionee shall be considered to be an Employee for so long as he or she remains in the employ of the Company or one or more Parent or Subsidiary, subject to the control and direction of the employer entity not only as to the work to be performed but also as to the manner and method of performance.

(D)Stockholder Rights.  An Optionee shall have no stockholder rights with respect to any shares covered by the Option until such individual shall have exercised the Option by written notice to the Company, paid the Option price for the purchased shares and been issued a stock certificate for such shares.

(E)Extension of Exercise Period. The Committee shall have full power and authority to extend the period of time for which any Option granted under this section is to remain exercisable following the Optionee's cessation of Service or death from the limited period in effect under this section to such greater period of time as the Committee shall deem appropriate; provided, however, that in no event shall such Option be exercisable after the specified expiration date of the Option term.


VIII.  
NON-TRANSFERABILITY OF OPTIONS.

An Option may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent and distribution and may be exercised, during the lifetime of the Optionee, only by the Optionee.

IX.  
ADJUSTMENTS UPON CHANGES IN CAPITALIZATION OR MERGER.

Subject to any required action by the shareholders of the Company, the number of Shares covered by each outstanding Option, and the number of Shares which have been authorized for issuance under the Plan but as to which no Options have yet been granted or which have been returned to the Plan upon cancellation or expiration of any Option, as well as the price per Share covered by each such outstanding Option, shall be proportionately adjusted for any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock, or any other increase or


decrease in the number of issued shares of Common Stock effected without receipt of consideration by the Company; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been "effected without receipt of consideration." Such adjustment shall be made by the Committee, whose determination in that respect shall be final, binding and conclusive.  Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of Shares subject to an Option.

In the event of the proposed dissolution or liquidation of the Company, the Option will terminate immediately prior to the consummation of such proposed action, unless otherwise provided by the Committee.  The Committee may, in the exercise of its sole discretion in such instances, declare that any Option shall terminate as of a date fixed by the Committee and give each Optionee the right to exercise his Option as to all or any part of the Optioned Stock, including Shares as to which the Option would not otherwise be exercisable.  In the event of the proposed sale of all or substantially all of the assets of the Company, or the merger of the Company with or into another corporation in a transaction in which the Company is not the survivor, the Option shall be assumed or an equivalent option shall be substituted by such successor corporation or a parent or subsidiary of such successor corporation, unless the Committee determines, in the exercise of its sole discretion and in lieu of such assumption or substitution, that the Optionee shall have the right to exercise the Option as to all of the Optioned Stock, including Shares as to which the Option would not otherwise be exercisable.  If the Committee makes an Option fully exercisable in lieu of assumption or substitution in the event of such a merger or sale of assets, the Committee shall notify the Optionee that the Option shall be fully exercisable for a period of 30 days from the date of such notice, and the Option will terminate upon the expiration of such period.

X.  
TIME OF GRANTING OPTIONS.

The date of grant of an Option shall, for all purposes, be the date on which the Committee makes the determination granting such Option.  Notice of the determination shall be given to each Employee or other person to whom an Option is so granted within a reasonable time after the date of such grant.  Within a reasonable time after the date of the grant of an Option, the Company shall enter into and deliver to each Employee or other person granted such Option a written Stock Option Agreement as provided in Sections II and XIV hereof, setting forth the terms and conditions of such Option.


XI.  AMENDMENT AND TERMINATION OF THE PLAN

(A)Amendment and Termination.  The Committee may amend or terminate the Plan from time to time in such respects as the Committee may deem advisable; provided that, the following revisions or amendments shall require approval of the shareholders of the Company holding a majority of the outstanding voting stock of the Company, who are present or represented and entitled to vote thereon:



(i)  An increase in the number of Shares subject to the Plan above the number of Shares set forth in Section III of the Plan, other than in connection with an adjustment under Section IX of the Plan; and/or

(ii)  Any material amendment under the Plan that would have to be approved by the shareholders of the Company for the Committee to continue to be able to grant Options under the Plan.

(B)Effect of Amendment or Termination. Any such amendment or termination of the Plan shall not affect Options already granted and such Options shall remain in full force and effect as if the Plan had not been amended or terminated, unless mutually agreed otherwise between the Optionee and the Committee, which agreement must be in writing and signed by the Optionee and the Company.

XII.  
CONDITIONS UPON ISSUANCE OF SHARES.

Shares shall not be issued pursuant to the exercise of an Option unless the exercise of such Option and the issuance and delivery of such Shares pursuant thereto shall comply with all relevant provisions of law, including, without limitation, the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, applicable state securities laws, and the requirements of any stock exchange upon which the Shares may then be listed, and shall be further subject to the approval of legal counsel for the Company with respect to such compliance.

As a condition to the exercise of an Option, the Company may require the person exercising such Option to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares and such other representations and warranties which, in the opinion of legal counsel for the Company, are necessary or appropriate to establish an exemption from the registration requirements under applicable federal and state securities laws with respect to the acquisition of such Shares.

XIII.  
RESERVATION OF SHARES.

The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan.  Inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company's legal counsel to be necessary for the lawful issuance and sale of any Share hereunder, shall relieve the Company of any liability relating to the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained.

XIV.  
OPTION AGREEMENT.

Each Option granted to an Employee or other persons shall be evidenced by a written Stock Option Agreement in such form, as the Committee shall approve.  In the event of conflict


between the terms of this Plan and the terms of a Stock Option Agreement, the terms of the Plan shall prevail and supersede the terms of the Agreement.

XV.  
INFORMATION TO OPTIONEES.

The Company shall provide to each Optionee, during the period for which such Optionee has one or more Options outstanding, copies of all annual reports and other information which are provided to all shareholders of the Company.  The Company shall not be required to provide such information if the issuance of Options under the Plan is limited to key employees whose duties in connection with the Company assure their access to equivalent information.

XVI.  
GENDER.

As used herein, the masculine, feminine and neuter genders shall be deemed to include the others in all cases where they would so apply.

XVII.  
CHOICE OF LAW.

All questions concerning the construction, validity and interpretation of this Plan and the instruments evidencing options will be governed by the internal law, and not the law of conflicts, of the State of Florida.

IN WITNESS WHEREOF, the Company has caused its duly authorized officer to execute this Plan effective as of July 26, 2007.

IMAGING DIAGNOSTIC SYSTEMS, INC.

By: /s/ Timothy B. Hansen
Name: Timothy B. Hansen
Title:   Chief Executive Officer

ATTEST:

By: /s/ Allan L. Schwartz
Name: Allan L. Schwartz
Title:   Secretary

(SEAL)
 
 
2212